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NETWORK MODELS FOR CAPTURING MOLECULAR FEATURE AND 
PREDICTING DRUG TARGET FOR VARIOUS CANCERS 
Network-based modeling and analysis have been widely used for capturing 
molecular trajectories of cellular processes. For complex diseases like cancers, if we 
can utilize network models to capture adequate features, we can gain a better insight 
of the mechanism of cancers, which will further facilitate the identification of molecular 
vulnerabilities and the development targeted therapy. Based on this rationale, we 
conducted the following four studies: 
A novel algorithm ‘FFBN’ is developed for reconstructing directional regulatory 
networks (DEGs) from tissue expression data to identify molecular features. ‘FFBN’ 
shows unique capability of fast and accurately reconstructing genome-wide DEGs 
compared to existing methods. FFBN is further used to capture molecular features 
among liver metastasis, primary liver cancers and primary colon cancers. 
Comparisons among these features lead to new understandings of how liver 
metastasis is similar to its primary and distant cancers. 
‘SCN’ is a novel algorithm that incorporates multiple types of omics data to 
reconstruct functional networks for not only revealing molecular vulnerabilities but also 
predicting drug targets on top of that. The molecular vulnerabilities are discovered via 
tissue-specific networks and drug targets are predicted via cell-line specific networks. 
SCN is tested on primary pancreatic cancers and the predictions coincide with current 
treatment plans. 
v 
‘SCN website’ is a web application of ‘SCN’ algorithm. It allows users to easily 
submit their own data and get predictions online. Meanwhile the predictions are 
displayed along with network graphs and survival curves.  
‘DSCN’ is a novel algorithm derived from ‘SCN’. Instead of predicting single 
targets like ‘SCN’, ‘DSCN’ applies a novel approach for predicting target combinations 
using multiple omics data and network models.  
In conclusion, our studies revealed how genes regulate each other in the form 
of networks and how these networks can be used for unveiling cancer-related 
biological processes. Our algorithms and website facilitate capturing molecular 
features for cancers and predicting novel drug targets. 
 
Xiaowen Liu, PhD, Co-Chair 
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Modern system biology focuses on understanding how genes and other 
molecules work in concert as a complex system to form and regulate biological 
processes in every living organism [1]. These regulations consist of various types: Cis-
regulatory elements and trans-regulatory elements are two main regulatory types [2]. 
Cis-regulatory elements are present near the structural portion of the gene/protein as 
the gene they regulate, such as the photosynthetic protein family, are expressed at the 
same time in development. Whereas trans-regulatory elements can distantly regulate 
genes from which they were transcribed. Enhancers and multiple trans-acting factors 
are essential for trans-control transcription initiations. Regulators contain DNA 
epigenetic modifications by methylation, miRNA, transcription factors (TFs), and post-
translational modification (PTM) that include histone proteins and other proteins, which 
are involved in methylation, phosphorylation, acetylation, ubiquitylation, and 
sumoylation (Figure 1). A motif is a sequence pattern that carries out certain functions 
in DNA, RNA and proteins. Normally, TFs coded by a gene can regulate gene 
expression by binding to specific motifs. MicroRNAs (miRNAs) regulate gene 
expression via RNA silencing or post-transcription regulations. Histones can alter the 
chromatin structure, which further controls the access of TFs and polymerases to 
genes thus resulting in an expression regulation [3]. Methylation plays a crucial role in 
regulating gene expression by blocking the promoters that can activate TFs [4]. Large 
experimental evidence has been gathered to verify biology gene interactions, such as 
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KEGG [5], Pathway Commons [6], MetaCyc Metabolic Pathway Database [7], JASPAR 
CORE [8], HistoneDB 2.0 [9], and miRGator v3.0 [10], GeneHancer [11], etc.  
A GRN is composed of functional linkages between regulators and targets on 
genome, transcriptome, and proteome levels (Figure 1). All stated interaction types 
can be integrated into GRNs to be studied systematically. Thus, Accurate 
reconstructing a GRN is one of the key tasks in systems biology. Recent advances in 
high-throughput techniques provide an opportunity to reconstruct regulatory networks, 
by offering a huge amount of binding data, like DNA-Seq, RNA-Seq, ChIP-Seq, and 
Mass spectrometry data [12]. Subsequently, various studies have been conducted for 
reconstructing GRNs using single or combinations of these types of data. For instance, 
Tong et. al. utilizes experiment-derived results and computational predictions to 
reconstruct a genetic interaction network that covers the entire yeast genome [13]. 
Margolin et. al. reconstructed a genome-wide co-expression network for humans by 
applying mutual information theory [14]. Stelzl et. al. reconstructed the whole proteome 
protein-protein interaction network using yeast two-hybrid system [15]. However, 
GRNs reconstructed by most of the previous work are general GRNs for different 
organisms, which cannot completely reflect the cellular machinery under the influence 
of diseases, i.e. cancers.  
To better understand the cellular processes in a context-specific setting, in this 
thesis, we attempt to reconstruct cancer-specific regulatory networks from various 
omics-data to reveal cancer-related features from a network perspective. In section 2, 
different types of GRNs and the underlying theory for predicting them are introduced. 
3 
Evaluation schemes and applications of these GRN models are described. In section 
3, an approach called ‘FFBN’ is introduced for reconstructing GRNs using Bayesian 
network models for identifying molecular similarities and differences between primary 
cancers and metastatic cancers using gene expression data. In section 4, ‘SCN’ 
approach is introduced as a tool for reconstructing functional networks for predicting 
drug targets for cancers using omics-data from all three levels of the central dogma. 
In section 5, a web application ‘SCNwebsite’ is introduced as a web extension of ‘SCN’ 
that allows users to conveniently predict drug targets online. In section 6, an algorithm 
called ‘DSCN’, which is the extension work of ‘SCN’, for predicting target combinations 




2.1 Reconstructing Gene regulatory networks 
Reconstructing a GRN that incorporates genes and other molecules help to 
gain a better understanding of biological processes underlying every living organism 
[16]. Currently, various studies have been conducted for reconstructing GRNs at each 
level of central dogma (Figure 2). For instance, Baryshnikova et al utilized DNA-seq 
data to generate genetic interaction network for yeast to better understanding genetic 
variants responsible for disease in humans [17]. Madan et al reconstructed co-
expression networks to systematically study interactions between transcription factors 
and their target genes in E.coli from expression data [18]. Databases like STRING [19] 
offer Protein-protein interaction networks, in which interactions are curated from 
experiments and existing databases. However, A functional network, which is usually 
generated from the integration of multiple types of omics data, can precisely capture 
the heterogeneity of diseases and biological processes from a comprehensive 
perspective. Wang et al. integrated expression and methylation data to generate a 
functional network that reveals subtypes of cancer, which hasn’t been classified before 
[20]. are The inference of a GRN is often accomplished through the use of gene 
expression data. So far, there are numerous computational methods and models 
developed for restoring GRNs in a real cellular environment. However, each of them 
has their assumptions and methods, drawing different blueprints that the GRN 
described. There is still much confusion about the basic meaning of GRN, ways of 
assessment, and possible biomedical application. Typically, the relationships between 
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genes are directional in nature and they can change over time or in response to 
external stimulus. Researchers are facing the choice of whether to include extra 
features such as causality and temporal behaviors when modeling gene networks or 
not.  
2.1.1 Gene interaction network 
Genes are said to be interacting if mutations in two or more genes cause 
phenotypical changes [21]. Positive gene interactions indicate beneficial events such 
as two mutations generating less severe phenotype while negative gene interactions 
suggest defective events such as synthetic lethality or reduced fitness [22]. 
Constructing gene interaction networks can illustrate how consistent sets of negative 
or positive gene interactions are when connecting protein complex and pathways to 
map a functional wiring diagram [21]. Previously, screening techniques can only 
analyze interactions within a relatively simple genome such as yeast. Recently, 
genome-wide application of CRISPR (clustered regularly interspaced short 
palindromic repeats)-Cas9 screening approaches have enabled researchers to draw 
whole-genome genetic interaction networks in human cells [23-25].  
2.1.2 Co-expression network 
A GRN built with a correlation-based method from RNA data is called a co-
expression network [26]. A co-expression network is constructed by calculating 
pairwise correlations for each gene pairs to form a fully connected graph, and a 
threshold scheme is applied to remove edges between genes that are not significantly 
correlated (Figure. 3a). Pearson Correlation, Spearman Correlation, and Euclidean 
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Distance are widely used for measuring linear correlations while Mutual Information 
(MI) and kernel correlations between two genes are the representative measures for 
detecting non-linear correlations [27]. P-value, Z-score, clustering coefficient [28], and 
random matrix theory [29] are typical threshold schemes for filtering out low content 
co-expression.   
Pearson correlation 𝜌𝜌 is the most basic correlation that measures the pairwise 





Here X and Y denote expression levels of two genes. Cov is the covariance between 
gene X, Y, and sigma 𝜎𝜎  indicates the individual standard deviation. Pearson 
correlation measures the collinearity between two genes with the assumption that both 
genes’ expression levels follow an approximately normal distribution, making it 
unsuitable for measuring genes with nonlinear relationships. 
Rank-based correlation describes correlations by comparing the rank of the 
variables (genes) instead of covariance. Take Spearman Correlation as an example, it 
compares the monotonic relationship between two variables (gene). If two genes follow 
the normal expression pattern and have a clear linear relationship, then Pearson 
Correlation and Spearman Correlation would be very similar. However, if two genes 
are monotonically correlated not linearly correlated, only Spearman Correlation could 
measure the non-linear relationships. In other words, Spearman Correlation is more 
general and robust compared to the Pearson Correlation, even though information gets 
lost during the ranking transformation.  
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Distance-based correlation mainly refers to Euclidean Distance, which is the 
geometric distance between two genes if two genes are assumed to be in the same p-
dimensional Euclidean space. Euclidean distance is sensitive to transformations, 
whereas the other two are normally invariant to linear transformations.  
Information-theoretic entropy and mutual information concepts provide a new 
perspective to scale the correlation between variables. Entropy measures the quantity 
of information within a given system and two variables that contain more entropy tend 
to be more related.  
Mutual information (MI) measures all the entropy within a system, including 
marginal entropy from variables and joint entropy between/among variables. A MI 
𝐼𝐼(𝑋𝑋,𝑌𝑌) measures a system of two variables (genes) and can be defined as: 
𝐼𝐼(𝑋𝑋,𝑌𝑌) = 𝐻𝐻(𝑋𝑋) +𝐻𝐻(𝑌𝑌) −𝐻𝐻(𝑋𝑋,𝑌𝑌) (2) 
where  




is the marginal entropy and: 




is the joint entropy for two continuous variables of gene X and Y.  
Relevance network A gene association network built with MI is called a 
relevance network (Butte and Kohane, 2000). ARACNe (Margolin et al., 2006) is the 
most famous and representative algorithms for building a relevance network. ARACNe 
assumes genes following a normal distribution and performed a Gaussian Kernel 
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estimator (Scott and Sheather, 1985) to estimate marginal distribution f(x) and joint 
distribution f(x,y) in formula 3 and 4. ARACNe defined its edge-pruning thresholds 
named data processing inequality (DPI) as: for all available triplets < 𝑖𝑖, 𝑗𝑗,𝑘𝑘 > , if 𝑖𝑖 
interacts with 𝑘𝑘 via 𝑗𝑗, then the edges (pairwise MI) among them should satisfy the 
following inequality:  
 𝐼𝐼(𝑖𝑖, 𝑗𝑗) ≤ 𝑚𝑚𝑖𝑖𝑚𝑚(𝐼𝐼(𝑖𝑖, 𝑘𝑘), 𝐼𝐼(𝑘𝑘, 𝑗𝑗)) (5) 
meaning that the indirect interaction in the system should contain the smallest MI value. 
Any violated indirect interactions will be pruned.  
GRN based on correlations provide co-expression or co-functionality from a 
network scale with no directionality, meaning that if no prior knowledge is provided (e.g. 
a gene is confirmed to be a transcription factor in a two-gene interaction system). In 
this case, causations among genes in a GRN cannot be reflected. MI detects 
underlying correlations that linear Pearson Correlation cannot discover, especially for 
variables with non-linear correlation. 
2.1.3 Protein-protein interaction network 
Protein-protein interaction (PPI) network reflects a network representation of 
all PPIs within a system, e.g. an organism’s cell. PPIs are either experimentally verified 
or inferred by their properties. Experiments such as yeast two-hybrid screening [30] 
and affinity purification couple to mass spectrometry [31] can detect in vivo PPIs. 
Inference based methods predict PPIs based on their structure [32], functional domain 
[33], or binding sites information [34]. The interactions (edges) in PPI networks can be 
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weighted and directed. The weights indicate the belief in an association [35] while 
directions provide information about the signal flow [36]. 
2.2. Network models 
Figure 3 lists some representative network models in current day's GRN reconstruction. 
In this figure, a column indicates a co-expression network; b column indicates a 
regression-based regulatory network; c column indicates a Bayesian network model; 
d column indicates a differential equation-based regulatory network; e column 
indicates dynamic Bayesian network 
2.2.1 Bayesian network 
A Bayesian network (BN) is a probabilistic network model that takes a group of 
random variables and measures their relationships as a directed acyclic graph (DAG) 
with all the conditional dependencies among them (Figure. 3(c)). Given a certain 
network structure G, a BN can be expressed as the following joint probability density 
function (PDF): 






𝑔𝑔 is the set of parents of gene node 𝑥𝑥𝑖𝑖 in a graph G, node 𝑔𝑔 ∈ 𝐺𝐺, 𝜃𝜃𝑖𝑖 is the 
i-th distribution mean, where all gene expression obeys a normal distribution N(𝜃𝜃𝑖𝑖, 𝛿𝛿𝑖𝑖). 
The product of them indicates the local Markov property of BN: Every node (gene) is 
conditionally independent of its non-descendants given its parents. Reconstructing a 
BN from the given expression data requires two types of inferences: (1) Parameter 
learning, which infers marginal and conditional distributions of all nodes, and (2) 
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structure learning, which infers the optimal topology that has the biggest overall 
probability.  
Parameter learning In parameter learning, the marginal distributions can be 
either given by prior knowledge or inferred by various methods such as the principle 
of maximum entropy [37] while conditional distributions are often inferred with 
approaches such as maximum likelihood estimator or expectation maximization [38].  
Structure learning Learning the optimal structure of a BN has been a great 
challenge for decades. One can always use a brute force approach to go through every 
possible structure and finally identify the best, which would result in exponential time 
complexity to achieve. Thus, most of the existing algorithms for searching the optimal 
structures are heuristic and progressive. For instance, Monte Carlo Markov chain 
(MCMC) methods use approximate sampling approaches [39]. Greedy equivalence 
search (GES) proposed a local optimal constraint and performed a stepwise searching 
scheme [40].  
Advantages and bottlenecks Compared to undirected co-expression 
networks, BNs can point out the directionality of each edge thus revealing a causation 
relationship among all genes, which is significantly advantageous. Large number of 
experiments have shown that BN can offer better accuracy and tolerance with noise 
expression input on a small number of genes [41]. As more variables (genes) are 
incorporated into the model, the computational time grows exponentially, which brings 
up the great challenge of building a whole genomic BN for higher organisms like 
humans [41]. Moreover, for one dataset, there might be more than one optimal BN 
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structure that has the equivalent overall probabilities. These models (structures) are 
called equivalence class [40], in which each model is probabilistically indistinguishable. 
For instance, two BNs 𝐴𝐴 → 𝐵𝐵 → 𝐶𝐶 and 𝐶𝐶 → 𝐵𝐵 → 𝐴𝐴 are probabilistically equivalent 
since their overall probabilities are 𝑃𝑃(𝐴𝐴)𝑃𝑃(𝐵𝐵|𝐴𝐴)𝑃𝑃(𝐶𝐶|𝐵𝐵) and 𝑃𝑃(𝐶𝐶)𝑃𝑃(𝐵𝐵|𝐶𝐶)𝑃𝑃(𝐴𝐴|𝐵𝐵) are 
the same. However, their directions are completely reversed. 
Causal network Causal network (CN) refers to a stricter form of BN, meaning 
not only conditional dependencies but also Markov conditions among variables need 
to be followed in the DAG, which provide clear causation of one variable over another. 
Hence, the above BN are not causally equivalent due to different Markov conditions: 
𝐴𝐴_||_𝐵𝐵|𝐶𝐶 (A is independent of C given B) versus 𝐶𝐶_||_𝐴𝐴|𝐵𝐵 (C is independent of A given 
B), where in the first network, A causes C, in the second, C causes A. Hence, causal 
network inference provides a more explicit interpretation of relationships among 
variables compared to BN.  
D-separation  D-separation measures a state of dependencies of two 
variables in a triplet. In the following connected triplets (7), (8), (9), and (10), (10) is 
defined D-separated while the rest are called D-connected. According to Pearl [42], in 
(4), 𝐵𝐵 blocks the information transmission between 𝐴𝐴 and 𝐶𝐶 .Thus in the case, 𝐴𝐴 
and 𝐶𝐶  are independent and Vice versa. Given this property, for a triplet with 
undirected edges 𝐴𝐴 -- 𝐵𝐵-- 𝐶𝐶, if the calculated correlation between 𝐴𝐴 and 𝐶𝐶 is lower 
than a given threshold, then the edges can be quickly oriented as 𝐴𝐴 ← 𝐵𝐵 → 𝐶𝐶, which 
saves a great deal of computational time.  
𝐴𝐴 ← 𝐵𝐵 → 𝐶𝐶  (7) 
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𝐴𝐴 ← 𝐵𝐵 ← 𝐶𝐶  (8) 
𝐴𝐴 → 𝐵𝐵 → 𝐶𝐶  (9) 
𝐴𝐴 → 𝐵𝐵 ← 𝐶𝐶  (10) 
2.2.2 Functional network 
While PPI networks provide evidence on how proteins physically interact with 
each other, functional networks connect genes with related functions even if they do 
not physically interact [43]. Functional GRNs are constructed to depict both direct and 
indirect regulations among genes. These regulations can be based on genetic 
interactions, co-expression, PPIs, and pathway data. Functional networks built with 
combinations of these data can provide comprehensive views for given phenotypes or 
diseases. For instance, co-expression data are frequently in concert with PPIs to 
obtain functional modules in yeast and human [44-46]. Combining pathways as 
skeleton and co-expression data as edge weights generate functional networks that 
reveal regulation differences among different cohorts, which further predict drug/target 
combinations [47-49]. 
2.2.3 Network analyses 
Degree Degree refers to how many connected neighbors a node has in a 
network. In a directed network, degree of a node is further divided into in-degree and 
out-degree. A node having significantly high degrees are considered hub node. In a 
GRN, a hub node usually provides higher impact towards the network than a non-hub 
node does. Degree distributions also reflect properties of a network. For instance, 
many biological networks have scale-free structure, in which very few nodes have very 
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high degrees while the other nodes have low degrees. A scale-free network has high 
resistance to network paralyze caused by random node failure. But if failures occur on 
hub nodes, the network will generally lose connectedness [50]. 
Module A Network module is defined as a subnetwork of highly connected 
nodes. Studying module properties and their changes across conditions help to identify 
similarities and differences between two networks [51]. These similarities/differences 
may lead to the breakthrough of biological problems. For instance, network modules 
are generated using multiple omics data and compared for identifying novel subtypes 
of various cancers [20]. On the other hand, modules (subnetworks) are simpler than 
the whole network. Studying modules can efficiently reduce the complexity and 
background noise introduced by the whole network. 
2.3 Model evaluation and Validations 
Evaluation metrics  A Bayesian information criterion (BIC) or Akaike’s 
information criterion (AIC) is chosen for measuring the goodness of fit of the learned 
structure [52]. BIC is defined as: 
𝐵𝐵𝐼𝐼𝐶𝐶 = 𝑚𝑚𝑛𝑛𝑚𝑚 �
𝑅𝑅𝑅𝑅𝑅𝑅
𝑚𝑚
� + 𝑘𝑘𝑛𝑛𝑚𝑚(𝑚𝑚) (11) 
Where RSS is the residual sum of square, n is the sample size and k is the number of 
parameters (nodes) in the model. To measure the accuracy of the model, Receiver 
operating characteristics (ROC) curve and Precision-Recall (PR) curve are often used. 
ROC curve is created by plotting true positive rate (X-axis) against false positive rate 
(Y-axis) under various threshold settings. Similarly, precision-Recall curve is defined 
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as plotting precision against recall under various thresholds. The four components of 
plotting these two curves are defined as follows: 
True Positive Rate=True Positives / (True Positives + False Negatives) (12) 
False Positive Rate= False Positives / (False Positives + True Negatives) (13) 
Precision = True Positives / (True Positives + False Positives) (14) 
Recall= True Positives / (True Positives + False Negatives) (15) 
Gold standards In computer science, Gold standard refers to criteria that is 
supported by scientific evidence. Typically, a gold standard contains both positive and 
negative set. A good algorithm or model should identify as many members as possible 
from positive set and vice versa from negative set. The quantity and quality of a gold 
standard can largely impact the prediction accuracy. For GRN reconstruction, the most 
common gold standards are from validated experiment results such as pathways and 
PPIs. Databases like Kyoto encyclopedia of genes and genomes (KEGG) [5] and Gene 
Ontology (GO) [53] provide validated gene interactions in the form of pathways. 
Databases like BioGrid [54] and STRING [32] offers evidence of PPI and protein 
complexes. Under given conditions, associations within these databases can be used 
as positive set and any associations beyond can be used as negative set. Notably, in 
‘Dialogue on Reverse Engineering Assessment and Methods‘ (DREAM) network 
inference challenge [55], validated regulations and regulation intensities are provided 
between certain transcription factors and target genes. Any regulations beyond them 
are considered as false regulation. Hence, a positive and a negative set are generated. 
Algorithms and models are tested with two sets to identify TP, FP, TN and FN. Under 
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all possible parameters, ROC curves and PR curves can be drawn. And the overall 
performance of algorithms and models can be measured by Area Under ROC (AUROC) 
and Area Under PR (AUPR) accordingly.  
2.4 Drug targets discovery 
Single drug target selection has been extensively studied recently while various 
methods have been developed. For instance, ‘Connectivity map’ project (C-map) 
curated expression profiles of human cells exposed to thousands of drugs, which can 
be served for drug repositioning [56]. Ma et. al developed an algorithm named ‘Met-
express’ [57] that combines gene co-expression network with human metabolic 
network to predict drug targets for pancreatic cancer. However, these methods only 
utilize expression data as fundamental knowledge and incorporate other biological 
knowledge to predict targets. However, most drugs function on protein level eventually. 
And expression level regulation might not eventually reflect on protein level. Secondly, 
their analysis lacks the support of cell survival phenotypes that directly reflect the effect 
of gene knockdown/knockout experiment.  
Combinational target wise, there are two existing studies that infer synergistic 
effect of combinational proteins that can be potentially treated as combinational targets. 
For instance, ‘OptiCon’ algorithm [49] takes advantage of existing pathways and 
mutation information to generate functional networks from expression data. Functional 
networks are further divided into subnetworks using bipartite network simplification 
approaches. Optimal control node for each network is identified and synergistic scores 
among optimal control nodes are calculated. ‘VIPER’ algorithm [58] applies the Master 
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Regulator Inference algorithm for identifying core regulators from a gene regulatory 
network generated from gene expression data. These synergistic core regulators can 
potentially be considered as candidate combinational targets. These methods focus 
on investigating the synergistic effect among protein, which can be treated as potential 
combinational targets. However, neither methods consider the durability of these 
protein combinations. Majority of their works are conducted on gene expression level. 
Other genomic properties like CRISPR-Cas9 screening efficiency of selected 
combinations are not evaluated or estimated, which might result in a failure of applying 
these combinations in vitro or in clinic. 
 
Figure 1 Central dogma and main regulate elements for biological networks 
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Figure 2 Central dogma and corresponding networks at each level 
 
Figure 3 Representative models for reconstructing regulatory networks 
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3 A fast and Furious Bayesian Network (FFBN) and Its Application to Identify 
Colon Cancer to Liver Metastasis Molecular Features 
3.1 Introduction  
Bayesian network (BN) is notoriously known for its slowness in achieving global 
optimal, especially when it is applied to the transcriptome data where thousands of 
genes are clustering together. However, BN is a powerful tool to discover regulatory 
relationships, especially suitable for biological conditions where the molecular 
mechanisms are largely unknown. One example is the colon to liver metastasis. 
Biologically, it is still unknown whether colon to liver metastasis is colon cancer or liver 
cancer. Clinically there is no effective therapy to treat them. Physicians are treating 
colon to liver metastasis either like a colon cancer or as a liver cancer, and there is no 
clear consensus. 
Causal network (CN) is a stricter form of BN. Constrained by Markov conditions 
among variables, CN reduces the ambiguous directions of edges thus more clearly 
reveal the real causations among variables, which could be critical during gene 
regulatory network (GRN) reconstruction. Here we proposed a searching algorithm 
‘FFBN’, which is derived from the famous FGS algorithm [59] used for searching the 
optimal model from a Causal network. Compared to FGS, ‘FFBN’ optimized the 
converging criteria and reduced unnecessary steps during model searching thus 
speeded up the whole reconstruction process. 
In this study, FFBN is applied on reconstructing GRNs for three sets of 
transcriptome samples: primary colon cancer (PC), primary liver cancer (PL), and 
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colon to liver metastasis (CLM) to build GRNs. By comparing three regulatory networks, 
top hubs that are uniquely existed in CLM network, commonly existed hubs between 
CLM-PC and CLM-PL respectively, are identified. After mapping hubs and their 
neighbors onto DAVID database [60], we observed a series of enriched pathways that 
may highly involve in molecular mechanisms related to colon to liver metabolisms. On 
top of that, several hub genes that highly regulates various members in the pathways 
as potential drug targets are selected. 
3.2 Materials and Methods 
3.2.1 Data availability 
In the study, all the microarray data (gene expression) is obtained from gene 
omnibus (GEO) database [61] of national center for biotechnology institute (NCBI). 
Since metastatic cancer study is relatively rare on GEO database, to make use of all 
possible datasets, a semi-automatic searching approach has been conducted: 
description pages (HTML) of all 67,362 datasets (May, 10th, 2016) from GEO are 
downloaded and traversed for searching title, summary and description paragraphs 
with key words “metastasis”, “metastatic”, “metastases” and platform constraints 
“AFFY”. Then from the remaining datasets, qualified datasets are selected with the 
following constraints: liver metastasis, colon cancer, liver cancer; tissue sample; AFFY 
U133A (GPL96) or AFFY U133PLUS2.0 (GPL570). Eventually, a subset of 9 datasets 
are considered qualified (Table 1). All the samples within are further classified into 
primary liver set (378 samples), primary colon set (186 samples) and colon to liver 
metastasis set (107 samples). 
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3.2.2 FFBN algorithm 
FGS algorithm FGS is a score-based algorithm which takes advantage of D-
separation concept and generates an optimal network structure. FGS consists of two 
phases: a ‘forward phase’ and a ‘backward phase’. Starting from an empty network, 
the ‘forward phase’ iteratively tries to add exactly one edge that has the highest 
‘Bayesian information criterion’ (BIC) score if this addition doesn’t create a cycle. The 
orientation of this edge is randomly given. This phase ends if no more edge addition 
can lead to an increase of BIC score. ‘Backward phase’ takes over the result from 
‘forward phase’ and tries to remove one edge at a time if the removal will not cause a 
score decrease. This phase terminates when no more edges can be removed from the 
network. Importantly, either an edge has been added or removed, the whole network 
would be converted back to a pattern, which means any edges that are not connected 
to the sink node in D-separated structures would be unoriented. Then Meek’s rules 
would be applied to re-orient some edges. In this process, unoriented edges might 
become oriented and incorrectly oriented edges might be corrected. 
Meek’s rule In the FGS algorithm, a series of rules called Meek’s rules (Figure 
4) [62] are applied to orient some of the undirected edges to convert the network to so-
called ‘pattern’ network.  
FFBN algorithm In FGS algorithm, the computation burden mainly lies in two 
parts: calculating BIC score for the new network structure and re-orienting edges with 
Meek’s rule at each step. Calculating BIC score is inevitable, so we developed FFBN 
algorithm that optimizes the re-orientation process (Displayed in Table 2). Instead of 
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applying R1-R4 after each edge insertion or deletion, FFBN applies Meek’s rules twice 
in the entire process, one after ‘forward phase’ and one after ‘backward phase’. This 
optimization significantly reduces the time complexity of the search process.  
As mentioned in section 2.2.1, D-separation can be used to quickly identify the 
orientations after determining the correlations between variables. In FFBN, conditional 
correlation is used to determine the correlation and then D-separation concept is 
applied to orient edges. For example, consider an edge 𝑋𝑋 → 𝑌𝑌 to be inserted into the 
network, where 𝑌𝑌 has a parent set [29]. FFBN then calculates the following probability 
P(𝑌𝑌|𝑍𝑍,𝑋𝑋) − P(𝑌𝑌|𝑍𝑍) , P(𝑌𝑌|𝑊𝑊,𝑋𝑋) − 𝑃𝑃(𝑌𝑌|𝑊𝑊)  and P(𝑌𝑌|𝑋𝑋,𝑍𝑍,𝑊𝑊) − 𝑃𝑃(𝑌𝑌|𝑍𝑍,𝑊𝑊) . If 
P(𝑌𝑌|𝑍𝑍,𝑋𝑋) − P(𝑌𝑌|𝑍𝑍) is the highest positive value, then clearly 𝑋𝑋 and 𝑍𝑍 together better 
explains 𝑌𝑌 in the model than separated. Thus 𝑌𝑌 should be the collider of both 𝑋𝑋 and 
𝑍𝑍. D-separation is then used to orient 𝑋𝑋 − 𝑌𝑌 − 𝑍𝑍 to 𝑋𝑋 → 𝑌𝑌 ← 𝑍𝑍. 
There are several parameters that control the density of the network: P is the 
penalty term in the BIC score formula. The lower the P is, the more likely edges are to 
exist in the network; D is the maximum degree of any node. This constraint is to prevent 
some specific nodes from becoming super hub nodes due to false collateral 
correlations between these nodes and the rest of the nodes. To add or delete an edge 
from the G, the BIC score must increase. 
3.3 Results 
3.3.1 Benchmark results 
DREAM challenge data [55] provides a series of gene expression datasets with 
golden standards, which are curated through biological experiment, thus highly reliable. 
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Hence, DREAM5 data is used as input to benchmark the performance of FFBN and 
FGS. The winner of the DREAM5 challenge: GENIE3 [63] is also incorporated into the 
benchmark as performance reference. DREAM5 consists of four networks, in silico 
network, S.aureus network, E.coli network and S.cerevisiae network. Each of which 
contains 1,643, 2,810, 4,511, 5,950 variables, respectively. The in silico and S. 
cerevisiae network, which is the smallest and largest network in DREAM5 dataset, are 
used in the benchmark for evaluating the performance of the three methods. 
Table 3 listed the benchmark result of three algorithms with two networks in 
DREAM5 dataset: For the smaller in silico network, GENIE3 provides the best AUROC 
(0.82) and AUPR (0.3) while has the highest speed among the three (Table 3(a)). FFBN 
maintains at least equally good AUROC and AUPR compared to FGS under different 
all parameters while offers an 11% to 75% faster searching speed. For S. cerevisiae 
network, three methods have an equal AUROC (~0.52) while FFBN and FGS have 
better AUPR (0.07) than GENIE3 (0.02) (Table 3(a)). Speed wise, GENIE3 still 
maintains the fastest speed. FFBN provides 19% to 96% speed increase compared to 
FGS (Table 3(b)).  
3.3.2 Constructing GRNs for liver cancer, colon cancer and colon to liver 
metastasis using FFBN on a whole transcriptome scale 
In total 14,213 common genes are included for reconstructing the GRN for 
three cancer subtypes. FFBN and FGS algorithm are executed on the supercomputer 
‘Carbonate’ at Indiana University with 16 cores and 100 GB RAM. Table 4 shows the 
total summary of constructed regulatory networks for CLM, PL and PC groups 
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respectively. After the GRN construction, 12,087 overlapped genes (nodes) are 
included among PL, PC, and CLM. In this study, any genes that have out-degree larger 
than 10 are defined as hub genes.  
3.3.3. Hub genes matching with oncoKB and Functional comparisons among 
subnetworks of CLM, PL and PC via pathways 
Hub genes regulate many other genes, thus play important roles in biological 
networks. A change of hub gene (mutations, expression level change, etc.) could 
significantly influence pathways and biological functions. In total, there are 118, 522 
and 223 hub genes existed in CLM, PL and PC network respectively. These hub genes 
across three cancer types are firstly mapped onto onco-KB [64], which is a knowledge 
base for all oncogenes supported by clinical evidence. Among all hub genes, 11, 44 
and 19 genes occur in onco-KB for CLM, PL and PC network respectively. 
Representative subnetworks for CLM, PL and PC respectively are then selected based 
on their unique CLM hubs, CLM-PL common hubs and CLM-PC common hubs 
indicated in Figure 5. Numbers in this figure indicates the number of hub genes (out-
degree > 10). There are 70 hubs unique to CLM, 13 common hubs between CLM and 
PL, and 25 common hubs between CLM and PC. They represent the unique 
subnetworks of CLM, the common subnetworks between CLM and PL, and common 
subnetworks between CLM and PC, respectively. All genes within subnetworks are 
then mapped onto DAVID for identifying enriched pathways.  
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3.3.4 Enriched pathways of unique CLM subnetworks 
Ten pathways were statistically significantly enriched among the 70 unique 
CLM subnetworks, P-value<0.05. Besides five pathways that are not obviously cancer 
related (e.g. Alzheimer’s disease pathway), the other five pathways represent unique 
aspects of the CLM malignant process. Among them, Metabolic pathway contains the 
largest number of enriched genes in the subnetworks. PHB is the largest hub gene 
with five neighbors: NME2, GSTZ1, CYP4F2, G6PC3 and ATP5G1 as representative 
actionable drug targets. Overexpression of PHB results in the up regulation of NME2 
and G6PC3, which plays a critical role in the metabolic pathway. 
Figure 6 lists four representative enriched pathways by CLM-unique hub genes 
and their neighbor genes. In this figure, Red dots are hub genes in CLM unique 
subnetwork while others are non-hub genes in the subnetwork; Green lines indicate 
the regulating directions. Proteasome pathway (Figure 6) is essential for various 
cellular processes, such as cell cycle regulation, which may cause oncogene 
mutations. It is also an important part of Ubiquitin-Proteasome Systems (UPS), which 
promotes cancer metastasis by regulating epithelial to mesenchymal transition (EMT) 
[65]. In insulin pathway (Figure 6), EMT modulates the secretion of insulin, and 
hyperinsulinemia is a risk factor of colon cancer and liver cancer [66]. SH2B2, a hub 
gene in the CLM network, regulates more genes in the insulin pathway than any other 
gene. SH2B2 plays a role in signal transduction from the receptor to the Shc/Grb2 
pathway and is highly related to the insulin pathway. 
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GnRH pathway (Figure 6) is responsible for the release of follicle stimulating 
hormone and luteinizing hormone from the anterior pituitary. Activation of the GnRH 
signaling pathway can activate several motigen-activated protein kinases (MAPKs), 
including extracellular-signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and 
p38 MAPK [65]. Notably, gene LHB regulates more genes in GnRH pathway than any 
other genes. It encodes the beta subunit of luteinizing hormone, which is controlled by 
GnRH.  
AMP-activated Protein Kinase (AMPK) pathway coordinates cell growth, 
autophagy and metabolism [67]. Recent studies indicate that the activation of the 
whole pathway can suppress tumor development and progression by regulating 
inflammation and metabolism [68]. In enriched AMPK pathway (Figure 6), 12 hub 
genes outside the pathway regulate 12 individual downstream genes involved in the 
pathway.  
3.3.5 Enriched pathways of CLM-PC common subnetworks 
Figure 7 lists two pathways that are commonly enriched by CLM-PC 
subnetworks. In this Figure, Blue lines, red lines and gray dash lines indicate 
regulations in PC, CLM and both networks respectively. Highlighted dots indicate hubs 
in the regulatory networks. Notably, in T-cell receptor signaling pathway (Figure 7), a 
large proportion of regulations (gray dashed line) are overlapped and the majority of 
them are from one gene, VAV3, which is a common hub in both CLM and PC 
subnetworks and regulates 28 common downstream genes, showing the expression 
consistency. This gene, along with its upstream genes, CFTR, SESN1 and LY6G6F, 
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are overexpressed in both CLM and PC compared to PL. Moreover, TRBC1 has the 
most regulations in the pathway, indicating its great regulatory impact on the pathway 
in both cases. Taken together, CLM and PC share a certain degree of similarity in terms 
of T-cell based immune response, given the numerous regulators and downstream 
genes that are present in both CLM and PC subnetwork.  
3.3.6 Enriched pathways of CLM-PL common subnetworks 
After ruling out non-cancer related pathways, remaining pathways are then 
classified them into two categories: immune response related pathways, including 
‘phagosome’ and ‘antigen processing and presentation’ and metabolic related 
pathways, including ’endocytosis’, ‘oxidative phosphorylation’ and ‘ribosome’. Among 
them, Oxidative phosphorylation (OXPHOS) pathway plays different roles in various 
cancer types. Normally, cancer cells have upregulated aerobic glycolysis compared to 
normal cells, with a concomitant downregulation of OXPHOS activity. Cancer cells 
prefer glycolysis over oxidative phosphorylation because the additional metabolites of 
glycolysis may benefit cell proliferation [69]. This phenomenon is called ‘The Warburg 
Effect’ and has been observed in many cancer types, including liver cancer. However, 
in many recent studies, a reversed ‘Warburg Effect’ -low regulation of glycolysis instead 
of high regulation of OXPHOS - have been found in certain cancer cells, including 
leukemia, lymphoma, pancreatic ductal adenocarcinoma and primary colon cancer [70, 
71]. Figure 8 indicates the different regulations between CLM and PL subnetwork in 
the commonly enriched OXPHOS pathway. Blue lines, red lines and gray dash lines 
indicate regulations in PL, CLM and both networks, respectively. Highlighted dots 
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indicate the common hub genes existing in PL and CLM. Interestingly, there is no 
common regulation (grey line) between these two subnetworks, which implies that 
CLM and PL have unique regulation mechanisms towards OXPHOS pathways.  
3.4 Discussion 
Human genome contains ~25,000 genes while Onco-KB covers 1,045 genes. 
Hence chi-square tests are performed to see if the frequency of hub genes that fall into 
onco-KB is significantly higher than background. All three networks show significantly 
higher frequencies with p<0.005, p<0.001 and p<0.012 for CLM, PL and PC 
respectively. This indicate that compared to randomly selected genes, hub genes are 
much more linked to cancer in three networks. This indicates the value of further 
investigating hub genes and their neighbors. 
The analysis results suggest that CLM has its own self-promoting and self-
regulating mechanisms via various pathways and core genes. For instance, GnRH 
pathway is enriched in the CLM unique subnetwork. Previous studies have shown that 
if GnRH receptor is expressed in cancer cells, then administering GnRH analogs 
reduces cancer proliferation and metastasis in vivo [72]. The results indicate that 
further investigation of the possibility of treating CLM with GnRH analogs may be 
worthwhile. In another enriched pathway ‘metabolic pathway’, Notably, a hub gene 
PHB regulates many targets, including NME2 and G6PC3. Both PHB and its targets 
NME2 and G6PC3 are over-expressed in CLM compared to PC. PHB acts as a trans-
acting regulatory RNA and plays a role in human cellular senescence and tumor 
suppression.  
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CLM and PL share certain GRN subnetworks related to immune response and 
metabolic pathways. Notably, the similarity is also present when considering the 
oxidative phosphorylation pathway, where hub gene ATP5B and its neighbor genes 
show consistent under-expression in CLM and PL compared to PC. This phenomenon 
clearly indicates the similarity between CLM and PL on energy generation. However, 
there are no common regulations between CLM and PL, indicating the existence of 
different inhibitory mechanisms towards this pathway.  
CLM and PC share similar immune responses. In T-cell receptor pathways, one 
common hub gene between CLM and PC is VAV3. VAV3 acts as an exchange factor 
for GTPases. This implies that CLM and PC share a very similar T-cell receptor-related 






Figure 4 Meek’s rules 
Figure 5 Overlap of hub genes for the CLM, PL, and PC regulatory networks  
Figure 6 Four representative pathways in CLM unique subnetwork  
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Figure 7 Regulations among genes involved in the T cell response pathway  
 
 








Table 1 Data composition and sources 
Subtype CLM PL PC 














Sample Size 107 378 186 
 
Table 2 FFBN algorithm description 
Algorithm FFBN (M): 
Input: a matrix M of N variables and S samples  
Output: a directed acyclic graph (DAG) G 
Parameters: BIC penalty P, maximum depth D 
1.       Calculate pairwise covariance matrix Mc for N variables; 
2.       Calculate Bayesian information criterion BIC for all possible edges from G; 
3.      Build set E={𝑒𝑒1, … 𝑒𝑒𝑛𝑛} , where each e is an edge causing positive BIC 
difference; 
4.       WHILE 𝐸𝐸 is not empty: 
5.               IF adding e result in no cycles and related nodes’ degree<D: 
6.                    G=G+e; 
7.                    E=E-e; 
8.                    Re-calculate BIC (G-e, P)-BIC(G, P) for each 𝑒𝑒 ∈ 𝐸𝐸 from 
updated G; 
9.                    G=Adjust_Direction(nt, G); 
10.             G=Convert_to_Pattern(G); 
11.             FOR each 𝑒𝑒 ∈ 𝐺𝐺: 
12.                   IF BIC(G-e, P)-BIC(G, P)>0: 
13.                        G=G-e; 
14.                        Re-calculate BIC (G-e, P)-BIC(G, P) for each 𝑒𝑒 ∈ 𝐺𝐺; 
15.    G=Adjust_Direction(nt, G); 
16.              G=Convert_to_Pattern(G); 
17.              RETURN G;           
Function Adjust_Direction (G): 
Input: a graph G and target node nt in an inserted edge 
Output: a graph with adjusted direction G’ 
1. FOR each edges e pointing to nt: 
2.            IF e is undirected: 
3.                 Orient e pointing to nt; 
4. RETURN G; 
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Function Convert_to_Pattern (G): 
Input: a graph G 
Output: a pattern graph G’ 
1.           Unoriented edges not involved in any v-structure in G; 
2.           Apply Meek’s rule R1, R2, R3 and R4. 
3.           RETURN G;  
Function BIC (G, P): 
Input: a graph G and penalty P 
Output: BIC score  
1.           BIC score = 𝑃𝑃ln(𝑚𝑚) 𝑘𝑘 − 2ln (𝐿𝐿�);  
2.           RETURN BIC score; 
Where: 
P is the penalty term of BIC; 
n is the number of samples for each variable’; 
nt is the target node of a directed edge. 
k is the number of nodes in the current network G; 
𝐿𝐿� is the likelihood of a specific network structure. 
𝐿𝐿� = ∏ 𝑝𝑝�𝑥𝑥𝑖𝑖,𝑥𝑥𝑗𝑗�𝑝𝑝𝑎𝑎𝑗𝑗𝐺𝐺 ,𝐷𝐷�𝑛𝑛𝑖𝑖=1   Where each 𝑝𝑝�𝑥𝑥𝑖𝑖 , 𝑥𝑥𝑗𝑗�𝑝𝑝𝑎𝑎𝑗𝑗𝐺𝐺 ,𝐷𝐷�  is the probability between 
node 𝑥𝑥𝑖𝑖 and 𝑥𝑥𝑗𝑗 given its parents set 𝑝𝑝𝑎𝑎𝑗𝑗𝐺𝐺  and dataset 𝐷𝐷 
 
Table 3 Benchmark results of FFBN and FGS  









FFBN 0.74 0.26 0.51 0.07 
FGS 0.72 0.25 0.52 0.07 
GENIE3 0.82 0.3 0.52 0.02 
 
3 (b) runtime comparisons. P indicates the penalty parameter used in calculating BIC. 
T indicate the trees generated for each gene in GENIE3  
Runtime 
(minutes) 
P=10 P=6 P=4 
In silico network 
FFBN 1.8 54.3 232.3 
FGS 2.0 67.2 404.5 







FFBN 121.2 1223.3 2022.5 
FGS 144.6 1921.8 3914.2 




















CLM 13,429 31,140 2,430 4,537 
PL 11,139 27,092 5,931 NA 
PC 11,273 17,091 4,299 8,399 
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4. SCN: Spectral Clustering for Network Based Ranking to Reveal Potential 
Drug Targets and Its Application in Pancreatic Ductal Adenocarcinoma 
4.1 Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic 
malignancy. Due to its wide heterogeneity, PDAC acts aggressively and responds 
poorly to most chemotherapies, causing an urgent need for developing new 
therapeutic strategies. Cell lines have been used as the foundation for drug 
development and disease modeling. CRISPR-Cas9 plays as a key tool for every step-
in drug discovery: from target identification and validation to preclinical cancer cell 
testing. Using cell-line models and CRISPR-Cas9 technology together makes drug 
targets prediction feasible. However, there is still a big gap between prediction results 
and actionable targets in real tumor. 
Network based analysis have greatly benefited cancer biology. So far, 
biological network has been used widely in numerous studies for identifying genes 
related to a certain therapy through curated database, specialized drug-protein [73] or 
protein-disease networks [74, 75]. (1) Curated databases, such as STRING protein-
protein interaction [19] network and KEGG [76] for pathway network, can provide 
complete genome wide networks that contains entire gene regulations, signal 
transductions and gene protein associations. However, these types of methods are not 
built for specific cancer types, making them too generalized. And it is also hard for 
people to analyze them as a whole. (2) drug-protein network is often used to 
investigate the mechanism of drug action and drug target prioritization [77]. For 
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instance, Isik et.al provided drug target identification by perturbed gene expression 
from Connectivity Map (CMAP) [56] and protein-protein Interaction (PPI) network 
information. However, these technologies did not directly connect drug with disease 
genes. (3) constructing protein-disease networks is another approach to identify 
genes-disease associations for selecting therapeutic targets in cancer [78]. Ferrero et 
al. proposed a semi-supervised network approach, which evaluates disease 
association evidence and make de novo predictions of potential therapeutic targets 
based on that [79]. These types of method fail to incorporate target information into 
their models to accurately predict drug targets. 
To better prioritize drug targets for PDAC, a method called ‘SCN’ that 
systematically utilizes expression data from tissue and cell-line, along with gene 
perturbation data and PPI network is proposed to select and rank druggable targets 
that effectively works on tissues. Systematically network structure comparing among 
the tumors and cell line models is used to discover the gene functional transfer among 
different models, and it is important to choose the most appropriate targets for patients. 
By connecting knockout of genome in cancer cell and cell death phenotype to observe 
patients network co-variation and select the optimum genes as potential targets. To 
our knowledge, this is the first-time people proposed a model to systematically predict 
potential targets by considering subnetwork similarity between tumors network and cell 
line network. On the other hand, ranked drug targets are validated by 1) mapping them 
onto existing PDAC drug targets; 2) applying pathway analysis on drug targets and the 
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clusters there are within, to show their functional associations with PDAC; 3) 
performing survival analysis for top ranked drug targets.  
4.2 Materials and Methods 
4.2.1 Materials 
Summary of all omics data involved in this studied can found in Table 5. 
Expression data of PDAC In total, expression data that is gathered from 263 
samples across three groups are used in this study, including 92 PDAC cell-line 
samples, 113 PDAC tissue samples and 58 adjacent normal pancreas tissue samples. 
These data are all from Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) database and all generated from Affymetrix Human 
Genome U133 Plus 2.0 Array, which contains 54,675 probes pointing to over 20,000 
genes.  
Protein-Protein Interaction network STRING [19] is a comprehensive and 
public pathway database (https://string-db.org/), which accumulates numerous prior 
knowledge of biological pathways and protein-protein interactions. STRING network 
protein links version 11 data is also included in this study.  
Genome wide CRISPR-Cas9 screening data and gene essentiality value 
To measure gene essentiality, CRISPR-Cas9 v3.3.8 screening data from ‘Project 
Achilles’ [80-82], (https://portals.broadinstitute.org/achilles) which includes genome 
wide CRISPR-Cas9 screening data that affect cell survival across 43 tumorous cell 
lines and genome wide RNAi screening data over 501 cell-lines is utilized in this study. 
We choose CRISPR-Cas9 over RNAi is because recent study has indicated that 
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compared to RNAi, CRISPR-Cas9 method has been proven to have less off-target 
effects, thus better for cancer drug-target related research [83]. In total, gene 
perturbation data of 74,222 sgRNAs on 17,733 genes across 22 PDAC cell-lines are 
included in this study. 
FDA approved drug targets All FDA approved drug and their targets are 
downloaded from Drug bank [5]. In total, all targets have been mapped onto 1,317 
genes, of which 283 genes are cancer drug targets.  
4.2.3 Methods 
SCN takes multiple types of omics data from tissue and cell-line data as input 
to rank druggable targets to recommend potential targets. SCN mainly consists of four 
steps (Figure 9): (A) Constructing integrated tissue PDAC network; (B) Constructing 
weight integrated gene perturbation network of PDAC cell by cells gene expression 
profiles and CRISPR-Cas9 genome perturbation; (C) Spectral clustering for 
subnetwork partition; (D) Graph structure similarity alignment between disease genes 
in tumors and gene perturbation networks in cancer cells and score to priority potential 
targets. 
STEP A: Construct an integrated network for tissue PDAC. The algorithm first 
compares tumor tissue and normal tissue expression profile to select overexpressed 
genes existed in tumor. Since the sample number of tissue tumor and normal groups 
are not equal, an unpaired T-test is performed while the corresponding p-value cut-off 
0.05 is used. Log fold changes between tumor and normal tissue samples are 
calculated for all significantly overexpressed genes. The algorithm then constructed a 
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correlation network by calculating Pearson correlation coefficient as edge weights. Log 
fold change is then used as the node weights in the network. The algorithm then maps 
integrated network onto STRING PPI network and selected the overlapped subnetwork. 
The rationale of mapping is that: 1. we believe high correlations among genes that also 
reflect on protein level are more likely to be true; 2. mapping both tissue integrated 
network and cell-line tissue integrated network onto the same PPI network makes them 
comparable via the PPI network. Eventually, a network with skeleton from PPI network, 
edge weights from pair-wise gene correlation, and node weights from Tumor -versus-
Normal log fold change is constructed. 
STEP B: Construct an integrated perturbation network of pancreatic cancer 
cells. Only genes that are selected in STEP 1 are picked from cell-line expression 
profile for integrated network construction. Similarly, pair-wise Pearson correlation 
coefficient of these genes are calculated to build a correlation network. The network is 
then mapped onto STRING PPI network and only the overlapped subnetwork is kept. 
Then gene essentiality value (gene knockout data) generated by CRISPR-Cas9 is then 
integrated into the network as node (gene) weights. Finally, two constructed networks 
share the same nodes and edges but with totally different node weights and edge 
weights. 
STEP C: Dimension reduction and network partition. In the network partition 
process, high dimension network is reduced to low dimension clusters thus common 
features among variables can be better captured from a graph perspective. Given a 
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graph G with n nodes and k categories, the objective function of spectral clustering 
can be described as： 
𝑚𝑚𝑖𝑖𝑚𝑚. 𝑐𝑐𝑐𝑐𝑐𝑐(𝐴𝐴1, …𝐴𝐴𝑘𝑘) =
1
2
∑ 𝑊𝑊(𝐴𝐴𝑖𝑖,𝐴𝐴𝑖𝑖)𝑘𝑘𝑖𝑖=1  (16) 
Where 𝑊𝑊(𝐴𝐴𝑖𝑖,𝐴𝐴𝑖𝑖) is the weight between cluster 𝐴𝐴𝑖𝑖 and its complement set 𝐴𝐴𝑖𝑖. This is 
well-known as RatioCut [84] problem and has been proven as an NP-hard discrete 
problem. To approximate the optimal solution, Spectral clustering [85] is applied to 
divide a network into clusters based on the spectrum (eigenvalues) of the 
corresponding similarity matrix. 
The general steps of performing spectral clustering can be described as: 






Where Sab in the matrix indicate the connectivity between variable a and b in the 
network. 






Where 𝑑𝑑𝑎𝑎 in the matrix indicate the degree (total edges) of variable a in the network. 
Clearly, 𝑑𝑑𝑎𝑎 = ∑ 𝑅𝑅𝑎𝑎𝑘𝑘𝑛𝑛𝑘𝑘=1  (19) 
3. Construct Laplacian matrix 𝐿𝐿′ = 𝐷𝐷 − 𝑅𝑅 (20) 





5. Perform singular value decomposition for matrix 𝐿𝐿 
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6. Pick top 𝐾𝐾 eigenvalues and their corresponding eigenvectors to generate a 𝑁𝑁 ∗
𝐾𝐾 matrix  
7. Perform K-means clustering [86] on the extracted matrix. 
Clearly, the Laplacian matrix 𝐿𝐿 consists of two types of node information: local 
information, which is node connectivity towards its neighbors in matrix 𝑅𝑅 ; global 
information, which is node degrees, or ‘influence’ towards the entire network. Hence, 
the clustering can be considered as selecting similar nodes based on their local and 
global similarities. Inspired by this idea, the Pearson Correlation Coefficient (CC) 
among nodes instead of the connectivity value (0 or 1) is used to fill up affinity matrix 
to measure the local similarities among genes. We also plugged log fold change of 
tumor versus normal expression value in degree matrix to indicate the global influence 










Where 𝑟𝑟𝑎𝑎𝑎𝑎 is the CC between gene a and b in tumor expression profile, and 𝐹𝐹𝐶𝐶𝑎𝑎 is 
the log fold change of gene when comparing its expression value in tumor group to 














Hence, the final Laplacian becomes 𝐿𝐿′ = 𝐷𝐷′ − 𝑅𝑅′′ (25). 
For K-means clustering, picking the optimal K could be arbitrary. In this study, 
K is equal to the number of eigenvalues that the algorithm picked. Too many or too few 
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eigenvalues will result in overfitting and underfitting respectively. Hence, an intuitive 
approach is applied: from K=1 to the number of total number of variables, K-means 
algorithm is performed while Hartigan’s number, which is a measurement of the 
clustering quality by comparing two clustering results, is calculated. For a K-means 
clustering, if the number is greater than 10, than having K+1-means clustering is of 
value [87]. The first K that result in the Hartigan’s number less than 10 will be selected, 
even though this scheme of picking K does not guarantee global optima.  
STEP D: Graph structure similarity alignment between subnetworks of 
dysregulation genes in tumors and perturbation networks in cancer cells and score to 
rank for priority potential targets. Spectral clustering is applied on tissue integrated 
network to look for genes that show common features. 1,317 targets (genes) for all 
FDA approved drugs are then mapped onto clusters. Then for the successfully mapped 
drug targets, the influence that each target might cause towards their clusters are 
evaluated. The assumption is that a drug target’s ‘influence' is limited in its cluster. In 
that case, a drug target’s influence towards any node is determined by the paths 
between them. Hence, given a graph G (V, E), where V and E are node set and edge 
set. Assume the node weight set is W and edge weight set is Y. For a drug target x, its 







𝑤𝑤ℎ𝑒𝑒𝑟𝑟𝑒𝑒 𝑌𝑌𝑖𝑖,𝑖𝑖_𝑛𝑛𝑛𝑛𝑥𝑥𝑛𝑛 ∈ E   
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Where ∏ 𝑌𝑌𝑖𝑖,𝑖𝑖_𝑛𝑛𝑛𝑛𝑥𝑥𝑛𝑛𝑥𝑥𝑖𝑖=𝑘𝑘  indicates the transmitted influence from target x to a node k via 
one possible path. Obviously, to maximize term (26), for every other node i, we need 






�   (27) 
Here, the term max�∏ 𝑌𝑌𝑖𝑖,𝑖𝑖𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛
𝑥𝑥
𝑖𝑖=𝑘𝑘 � represents the most correlated path between x and 
i. And we define term (27) as Target Influence score (TI). Subsequently, a scoring 
scheme is developed for calculating TI scores for all 367 drug targets.  
4.3 Results 
4.3.1 Potential target subnetworks and targets for PDAC by SCN algorithm 
identification 
Overlapping 15,664 common genes among 263 gene expression profiles tumor 
tissue, normal tissue and cell-line are included for SCN analysis, among which are 
7,376 genes are significantly dysregulated by non-paired t-test where p-value is less 
than 0.05. 4584 genes out of 7,376 genes are significantly over-expressed in tumor 
tissues group compared to normal tissue group. All 4,584 genes are then mapped onto 
STRING human PPI network. 4,144 genes have overlapped with PPI network. 367 out 
of 4,144 are drug targets of FDA approved drugs. In total, 4,141 genes and associated 
931,288 pairs of gene-gene interaction of network with 367 FDA approved drugs’ 
targets (which includes 90 cancer drug targets) are input into SCN algorithm to seek 
potential targets for PDAC patients.  
In total, 198 subnetworks (clusters) have been identified by SCN algorithm for 
PDAC patients. All 367 targets are scored and ranked by SCN system. Table 6 shows 
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the top ten targets and two well-known PDAC drug targets ranked by ‘SCN’. Column 
2 indicates the Rank predicted from SCN; Column 3 indicates cancer drug target 
information; Column 4 lists the average expression values in tumor tissue samples; 
Columns 5 lists average expression values in normal tissue samples; Column 6 
indicates log2 fold change of expression differences between tumor group and tissue 
group; Column 7 indicates T value from t test between tumor and normal group; 
Column 8 indicates P-value from T test between tumor and normal group. Column 9 
indicates gene essentiality value (Cell survival rate at T3 versus at T0). Positive values 
and Negative values indicate an enhanced and reduced cell survival rate respectively 
in vitro. of which POLE2 and DHFR are known cancer drug targets. ERBB2 and MTOR 
are PDAC drug targets. 
The 12 selected genes are all highly expressed in tumor tissue compared to 
normal tissue. Moreover, the loss of all 12 genes cause a reduced cell survival. Among 
them, two widely accepted targets ERBB2 and MTOR in treating PDAC are caught by 
SCN algorithm. PGK1, POLE2 and HMMR are the top three ranked targets. PGK1 is 
in a cluster of 41 genes. POLE2 and HMMR are together in a cluster 67 genes. Figure 
10 shows the expression level of two clusters containing top three ranked targets in 
tumor tissue, normal tissue and cell-lines. It can be observed that these genes show a 
concordant high expression pattern in cell-line and tumor than normal group.  
Figure 11 displays the compositions of the subnetworks of PGK1, POLE2 and 
HMMR as well as their expression pattern in tumor, normal and cell-line models. Cube 
node indicates known targets while circle node indicates other genes. Red and blue 
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lines indicate positive and negative correlations, respectively. Line shade indicates 
correlation intensity. Nodes are placed in a clockwise order by their ascending degrees.  
Subgraph (A) indicates the top ranked Drug targets ‘PGK1’ and the subnetwork of its 
cluster. Subgraph (B) indicates the second and third ranked Drug targets ‘POLE2’, 
‘HMMR’ and the corresponding subnetwork of their common cluster. Yellow 
highlighted genes are common genes between HMMR and POLE2. Subgraph (C), (D) 
and (E) are overall survival results from cox regression to test the top three ranked 
drug targets PGK1, HMMR and POLE2 respectively. 
Glycolytic enzyme phosphoglycerate kinase 1 (PGK1) is a gene that is coding 
for a glycolytic enzyme that catalyzes synthesis of 3-phosphoglycerate. Its functions 
and mechanisms haven’t been completely understood. As an inhibitor, PGK1 inhibits 
the secretion of vascular endothelial growth factor (VEGF) and interleukin-8, thus 
inhibits Angiogenesis [88]. However, multiple studies have suggested that in 
metastatic tumor cells, PGK1 plays a completely contrary role. Overexpression of 
PGK1 facilitates not only tumor growth and interaction with microenvironment, but 
tumor invasion and metastasis in liver, gastric and prostate cancer [89, 90]. In this 
study, PGK1 has been identified as the target that can cause the highest influence 
towards its cluster (shown in Figure 11(A)). It interacts not only with the greatest 
number of genes, but also with the greatest number of other targets in the cluster. Most 
of its correlations with its neighbors are positive.  
DNA Polymerase Epsilon 2, Accessory Subunit (POLE2) is high involved in 
DNA repair and replication. It has been previous reported to have high association with 
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colorectal cancer [91]. In this study, POLE2 is ranked as the second highest target. 
Even though its cluster is much larger than the cluster of PGK1 (shown in Figure 11(B)), 
the influence of POLE2 towards the whole cluster is not as strong as influence of PGK1. 
Hyaluronan Mediated Motility Receptor (HMMR), which is target with third 
highest score, is highly involved in cell motility. HMMR forms a complex with BRCA1 
and BRCA2, thus it has been identified as a high-risk factor in multiple cancer types 
such as breast cancer and fibrosarcoma [92, 93]. Interestingly, HMMR is in the same 
cluster with POLE2 (shown in Figure 4-5). Their degrees and ranks are very similar, 
implying their equally influence towards the whole cluster. 
4.3.2 Pathway enrichment analysis for top three ranked targets and their clusters 
For all 198 clusters, ‘Gene Set Enrichment Analysis’ (GSEA) are performed for 
getting enriched pathways [94]. ‘C5 go gene sets BP GO biological process’ database 
version 6.2, which contains 4,436 gene sets annotated by GO term with their functions, 
are selected as reference pathway database while significance level P<0.05 are used 
in pathway analysis. GSEA analysis required a ranked gene list to perform such 
analysis, so we used log fold change of tumor vs normal tissue as their weights and 
ranked them.  
The top ranked gene, PGK1 with its cluster, has significantly enriched 
‘CARBOHYDRATE_CATABOLIC_PROCESS’. The second and third gene, HMMR 
and POLE2, with their cluster, have significantly enriched multiple pathways such as 
‘CELL CYCLE’ and ‘MIOTOSIS’. These pathways are all highly related to cell cycle 
and cell division, suggesting these two genes along with their cluster members, are 
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critical components in regulation cell cycles. Moreover, HMMR and POLE2 enriched 8 
pathways of 11 total enriched pathways that are enriched by the entire cluster, 
suggesting common functional activities. 
4.3.3 Target selection validation by clinical outcomes 
Survival analysis for differentially expressed genes PGK1, HMMR and POLE2 
from public database ‘GEPIA’ (http://gepia.cancer-pku.cn/) are performed. GEPIA [95] 
is a public database containing 9,736 tumors and 8,857 normal samples from TCGA 
[96] and GTEx [97] projects. All three targets showed significant difference (Hazard 
ratio P-value<0.01) in patients’ survival (Figure 11 (c), (d), (e)) Low expression of these 
three genes provide significantly higher survival than high expression. Survival curves 
of all three genes show a similar pattern at around 20th months, in which low 
expression curves start to have a clear segregation from high expression curves. 
4.3.4 Targets accordance comparison between clinical drug treatment in 
pancreatic cancer and selection by SCN algorithm 
Amanam and Chung systematically investigated all currently available targeted 
therapies and drug targets for pancreatic cancer [98]. Los of studies have reported 
HER2 overexpression in up to 45% of patients with PDAC [99]. This is because HER2 
amplifications often occurs in PDAC [100]. Known drug targets are mapped to the 
ranks system and listed result in Table 6. 
In this study, HER2 are ranked 14th by SCN. SCN algorithm covered four out 
of top 100 only except to MAP2K1, of which ERBB2 and MTOR are ranked relatively 
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high (rank 14 and rank 32 respectively). All the missing targets are not included in 
4,414 genes for constructing integrated networks in the beginning.  
4.4 Discussion 
Tumor cells prefer glycolysis to oxidative phosphorylation for providing energy 
during proliferation and metastasis. This phenomenon is called ‘Warburg Effect’ [69] 
and often occurred in certain tumor types such as brain cancer, liver cancer and 
pancreatic cancer. PGK1 is an important enzyme in the metabolic pathways. Recent 
studies have revealed that PGK1 can promote cell proliferation and tumorigenesis by 
enhancing Warburg effect. For instance, Li et. al.’s study reveals that PGK1 functions 
as a protein kinase to phosphorylate PDHK1, which further promotes the Warburg 
effect in brain tumorigenesis [101]. Hu et. al recently reported that acetylation of PGK1 
can promote cell proliferation and tumorigenesis in liver cancer via glycolysis 
pathways[102]. Xie et. al.’s study has pointed out that PGK1 is highly involved in MYC-
induced metabolic reprogramming, which further causes a reinforced Warburg effect 
[103]. From the pathway analysis result from section 4.3.2, another significantly 
enriched ‘cellular metabolic process’ pathway is observed. This implies the activated 
Warburg effect in PDAC samples.  So far, there are studies that focus on targeting 
Warburg effect to treat pancreatic cancers. Rajeshkumar et. al has selected a small 
molecule called ‘FX11’, which inhibits a lactate dehydrogenase-A (LDH-A), a critical 
enzyme in metabolizing pyruvate, to block ‘Warburg effect’ [104]. They observed that 
for TP53 mutant cells, their approach can significantly increase tumor cell apoptosis. 
These studies provide the possibilities of targeting ‘Warburg effect’ to treat PDAC. 
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Hence, together with the survival analysis result shown in Figure. 11 (c), the findings 
suggested that PGK1 is a potential target that alternatively aims Warburg effects and 
thus worth further experiment validation. 
‘DNA polymerase epsilon 2’ (POLE2) and ‘Hyaluronan mediated motility 
receptor’ (HMMR) have previously reported as significantly hyper-expressed in both 
PDAC tissues and cell-line expression profiles [105]. Studies have linked HMMR and 
its product ‘Receptor for Hyaluronan Mediated Motility’ (RHAMM) to a variety of 
hematological malignancies and other solid tumors [106-108]. This is because 
RHAMM working in concert with BRCA1 and BRAC2, can significantly promote tumor 
growth and metastasis for pancreatic cancer [109] in vivo, and multiple other cancer 
types such as basal-like breast cancer [110] and glioma [111] in vivo. Hence, Willemen 
et. al pointed out of HMMR/RHAMM being a considerable potential target for cancer 
immunotherapy [112]. Moreover, Li, Ji and Wang has targeted HMMR via long 
noncoding RNA (lncRNA) and successfully suppressed Glioblastoma in mouse 
xenograft model [113]. This evidence suggest HMMR and its product RHAMM is worth 
further study for its potential to be used as PDAC drug target. POLE2 is highly involved 
in DNA repair and replication. However, targeting POLE2 to treat cancer is rarely 
reported. Li et. al used β-elemene, which is a type of elemane sesquiterpenoids, to 
suppress POLE2 expression and restrained lung adenocarcinoma cell malignant in 
vitro [114], which can be used as a evidence of treating pancreatic adenocarcinoma 





Figure 9 Workflow of ‘SCN’ algorithm 
 
Figure 10 Heatmap of PGK1 and POLE2-HMMR clusters in three groups 
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pancreas tissues  
1 GSE36133 (43) GSE42952 (33) GSE46385 (3) 
2 GSE46385 (7) GSE51978 (2) GSE16515 (16) 
3 GSE21654 (22) GSE16515 (36) GSE15471 (39) 
4 GSE17891 (20) GSE15471 (39)   
5   GSE23952 (3)   
Sample 
size 
92 113 58 
 
Table 6 The top 12 ranked drug targets and associated gene expression  
































PGK1 1 N 10.18 9.28 0.90 8.03 <0.01 -1.84 
POLE2 1 Y 5.87 4.83 1.04 5.31 <0.01 -1.31 
HMMR 2 N 6.83 5.06 1.77 4.31 <0.01 -0.96 
VDAC1 4 N 9.53 8.83 0.70 6.30 <0.01 -1.85 
PPP2CA 5 N 8.61 8.40 0.21 3.98 <0.01 -1.94 
DARS2 6 N 5.63 5.16 0.47 3.02 <0.01 -0.54 
TK1 7 N 6.56 5.95 0.61 3.37 <0.01 -0.42 
VARS 8 N 5.52 5.14 0.38 3.01 <0.01 -2.13 
DHFR 9 Y 7.09 6.45 0.64 3.75 <0.01 -1.06 
MMP14 10 N 7.40 6.51 0.89 4.37 <0.01 -0.21 
ERBB2 13 Y 6.65 5.58 1.07 3.23 0.01 -0.20 








5. SCN Website: Graphical Computation for Prioritization of Cancer 
Therapeutic Targets Using CRISPR–Cas9 Screen 
5.1 Introduction 
CRISPR screening technology can estimate the essentiality of given genes 
under different conditions. Thus, it has more often been applied in selecting novel 
target for guiding patient treatment. Numerous tools and databases are established to 
estimate gene essentiality and predict novel targets using whole genome CRISPR 
screening data across various cell-lines and cancer types. For instance, However, 
there is still in lack of interactive platforms for users to have customized targets 
recommendations. Li, Xu and Xiao et al. developed a mean-variance model based 
analysis tool (MAGeCK) that can prioritize novel essential genes and pathways under 
different experiment conditions [115]. Another tool called ‘NetICS’generated a graph 
diffusion-based model for prioritizing cancer genes using multiple types of omics data 
[116]. However, most of these tools can only be run locally without querying other 
databases, which result in limited resources of omics data for accurately prioritizing 
targets. Database wise, Rauscher et al. constructed a database ‘GenomeCRISPR’for 
high-throughput CRISPR-Cas9 screenings [117]. ‘Depmap’is another CRISPR-Cas9 
screening database that covers more than 20 major cancer types and over 400 cancer 
cell-lines [118]. Behan et al. utilized large-scale CRISPR-Cas9 screening and 
regression models to differentiate disease specific essential genes, universally 
essential genes and non-essential genes [119]. These databases don’t have a server-
client interactive interface. Users cannot upload their own omics data to get a 
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customized target prediction result. Based on the issues and needs mentioned above, 
the ‘SCN website’, an interactive tool for delivering customized drug targets and 
visualizations is developed. SCN algorithm provides a systematic way of prioritizeing 
potential targets from multi-omics data. And SCN website fills the gap between 
algorithms and databases, enabling users to upload their own expression data, 
calculate the result while query the databases. 
5.2 Materials and Methods 
5.2.1 Data content  
After crossing match data from all databases, we include and provide selected 
targets for 10 cancer types, namely: Colon adenocarcinoma (COAD), Esophageal 
carcinoma, (ESCA), Head and Neck squamous cell carcinoma (HNSC), Kidney renal 
papillary cell carcinoma (KIRc), Kidney renal papillary cell carcinoma (KIRP), Liver 
hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell 
carcinoma (LUSC), Pancreatic adenocarcinoma (PAAD), Thyroid carcinoma (THCA). 
These 10 cancer types have tissue expression data, corresponding cell-line data and 
CRISPR gene essentiality data and thus been included. 
Cell-line data across various cancer types cell-line expression data and 
CRISPR-Cas9 screening data (v3.3.8) are downloaded from database ‘Depmap’[118, 
120, 121] (https://portals.broadinstitute.org/achilles). These whole genome data is 
across >400 cell-lines and 24 most common cancer types. 
Protein-protein interaction network A protein-protein-interaction network 
consisting of 9,606 proteins (version ‘9606.protein.links.v11.0’) from STRING 
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database [32] is included in this study. It is a comprehensive database (https://string-
db.org/) that accumulates prior knowledge of biological pathways and protein-protein 
interactions. 
FDA approved drug targets all FDA approved drugs from Drug bank [122] 
(version 02/03/2018) are downloaded along with their targets. These targets are 
defined as FDA approved drug-targets. In total, there are 1,317 targets included in the 
database, which contains 283 targets of cancer drugs. 
Example tissue expression data of pancreatic cancer a set of example 
pancreatic tissue expression data from Gene Expression Omnibus [61] (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) database is provided. This set consists of 113 
Pancreatic ductal adenocarcinoma (PDAC) tissue samples and 58 adjacent normal 
pancreas tissue samples, all of which are generated from Affymetrix Human Genome 
U133 Plus 2.0 Array, which contains 54,675 probes pointing to over 20,000 genes. 
5.3 Implementation 
SCN is a free and publicly available website 
(https://pcm2019.shinyapps.io/SCNrank/). Both server and client ends are carried out 
by ‘Shiny’ package, which is a convenient solution that integrates PHP and back-end 
databases for setting up an interactive website on an R server. The website consists 
of four tiers (Figure 12): Data tier stores preprocessed omics data for the analysis; 
Computation tier executes SCN algorithm with data from both data tier and client to 
generate results. Interface tier allows users to upload their inputs, reflect the progress 
of the algorithm execution and provides sample input/ouput files; Output tier constructs 
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a table of statistics of ranked targets. Top targets are displayed in network images. 
Kaplan-meier curves are drawn for top targets to indicate how hazardous they are for 
patient survival.  
All omics data is stored locally as inputs of the algorithm. The SCN algorithm 
is written in R (3.6) and python (2.7.16), in which R program does the clustering and 
python program does the scoring. Networkx (1.9) package is called in python program 
for representing subnetworks and searching paths among nodes in subnetworks. 
Results of the algorithm are displayed as tables, Scalable Vector Graphics (SVG) and 
Portable Network Graphics (PNG) images. Tables are generated by R, network 
images are generated by Cytoscape (3.3) and Kaplan-meier curves are called from 
GEPIA database [123] using TCGA patient annotations.  
5.4 Functionalities 
Figure 13 generally lists all available results generated from SCN website. 
Subgraph A indicates workflow of SCN algorithm. Red, green, and yellow blocks 
indicate input from database, input from user and output respectively. Subgraph B 
shows an example output of ranked targets. Subgraph C displays an example of 
Kaplan-Meier curve from survival analysis. Subgraph D indicates an example output 
from Pathway analysis. Subgraph E indicates an example of corresponding clinical 
trials. 
Survival analysis 
SCN website queries GEPIA, which stores all TCGA and GTEx patient 
annotations, to get survival analysis result. The Kaplan-Meier curves, cox proportional 
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hazard ratio and the 95% confidence interval information are included in the plot 
(Figure 13 (c)). Clicking each gene in the list results in a Kaplan-Meier curve, which 
measures the survival differences of patients with high expression versus low 
expression levels of this gene. 
Clinical trials Proving evidence of clinical trials can connect prioritized targets 
with clinical research/studies. SCN website provides clinical trials across six cancer 
types: pancreatic cancer; breast cancer; osteosarcoma; soft tissue sarcoma; ovarian 
cancer and prostate cancer. As indicated in Figure 13 (B), these clinical trials 
information includes case number, treatment plan, overall survival and disease-free 
survival (DFS). All clinical trials information is gathered from Clinical Trials database 
from NIH (https://clinicaltrials.gov/). 
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Figure 12 Website Structures of data processing, output type and visualization 
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Figure 13 Example outputs of SCN website 
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6. D-SCN: A Spectral Clustering based Network approaches for Double drug-
Targets Prioritization for Cancers 
6.1 Introduction 
Pancreatic cancer is the third most lethal cancer types in the united states [124]. 
The American Cancer society has estimated that over 56,000 new cases and over 
45,000 new deaths of pancreatic cancer will occur during 2019 [124]. Over 85% of 
pancreatic cancer types are pancreatic ductal adenocarcinoma (PDAC). Compared to 
all other major cancer types, PDAC has the poorest 5-year survival (~8%). This is 
mainly due to late diagnosis: patients are usually diagnosed with PDAC at very late 
stages when tumor cells have already spread and metastasized to other organs, which 
limits the efficient treatment plans [125]. Moreover, Due to the treatment-recalcitrant 
characteristics [126, 127], PDAC cells often develops drug resistance, which 
undermines the effectiveness of both chemo drugs and targeted drugs [128]. 
Combinational drug treatment is considered as an alternative approach for its 
synergistic anticancer effects and reduced resistance of cancer cells [129]. 
Combinational therapy such as Gemcitabine plus Erlotinib or Gemcitabine plus Nab-
paclitaxel has been used in clinic for treating PDAC, however, the survival is modestly 
improved [126]. This creates an unmet need of identifying novel combinational 
therapies.  
Cell-lines derived from human cancers are widely used for understanding 
cancer biology and for testing hypotheses to facilitate the cancer treatment [130]. 
Despite that cell-line models allow investigators to observe and mimic a complete 
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PDAC process, the complexity of modelling PDAC cell-line has increased the difficulty 
[131]. Recent advances of CRISPR-Cas9 genome editing technology [132] enables 
large-scale preclinical testing and validation of therapeutic targets discovery [133]. 
Protein-coding genes within the whole genome can be simultaneously screened for 
the evaluation of their essentiality towards cancer cells [24, 134]. In the meantime, 
genome/transcriptome data generated from high-throughput technology offers a 
wealth of information for revealing the molecular mechanisms of PDAC, including 
cancer related genes that can potentially be targets [135]. These different types of 
omics data interpret PDAC from different angles. However, constructing models that 
utilize both CRISPR-Cas9 screening data and transcriptome date collected from 
patients and cancer cells to better prioritize potential targets remains to be explored.  
So far, various attempts of using omics-data to identify drug targets have been 
reported, including those either solely using one types of omics data or integrating 
multiple types of omics data.  
Single drug target selection has been extensively studied recently while various 
methods have been developed. For instance, ‘Connectivity map’ project (C-map) 
curated expression profiles of human cells exposed to thousands of drugs, which can 
be served for drug repositioning [56]. Ma et. al developed an algorithm named ‘Met-
express’ [57] that combines gene co-expression network with human metabolic 
network to predict drug targets for pancreatic cancer. However, these methods only 
utilize expression data as fundamental knowledge and incorporate other biological 
knowledge to predict targets. Moreover, Expression level regulation might not 
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eventually reflect on protein level regulation, on which most drugs function. Additionally, 
their analysis lacks the support of cell survival phenotypes that directly reflect the effect 
of gene knockdown/knockout experiment.  
Current methods for identifying combinational targets generally rely on network 
controllability theory [136]. Candidate target combinations are selected based on their 
controllability and potential synergistic effects over the networks. For instance, 
‘OptiCon’ algorithm [49] takes advantage of existing pathways and mutation 
information to generate functional networks from expression data. Functional networks 
are further divided into subnetworks using bipartite network simplification approaches. 
Optimal control node for each network is identified and synergistic scores among 
optimal control nodes are calculated. ‘VIPER’ algorithm [58] applies the Master 
Regulator Inference algorithm for identifying core regulators from a gene regulatory 
network generated from gene expression data. These synergistic core regulators can 
potentially be considered as candidate combinational targets. These methods focus 
on investigating the synergistic effect among proteins, which can be treated as 
potential combinational targets. However, neither methods consider the durability of 
these protein combinations. RACS [137] and DrugComboRanker [48] combines drug-
treated expression profiles with pathway information and anticancer drug information 
to prioritize combinational drugs from existing drugs from constructed functional 
networks. Taken together, all these methods are conducted mainly on expression level. 
Other genomic properties such as gene essentiality derived from CRISPR-Cas9 
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screenings are not evaluated or estimated, which might result in a failure of applying 
these combinations in vitro or in clinic. 
To resolve the stated issue, a method called ‘DSCN’ is proposed. It combines 
expression from patients and cell-lines with CRISPR-Cas9 data and proteomics data, 
to prioritize combinational targets. Inherited from SCN, a method that combines the 
same omics data to prioritize single target, DSCN constructs functional networks and 
mimics expression and essentiality changes of genes after targets being sequentially 
knocked-out. Combinational targets are then selected based on the sequential process. 
Moreover, another method called ‘DSCNi’, which utilizes similar processes of DSCN 
for predicting combinational targets for individuals, are also proposed. DSCNi takes 
one patient’s expression profile as input to predict ranked combinational targets for 
various cell-lines.  
6.2 Materials and Methods 
6.2.1 Materials  
Expression data (cell-line and tissue), perturbation data, PPI network and Drug 
target information are included as multiple types of omics data in the study. The 
composition and version of each omics-data type can be found from Table 7. 
Expression profiles We mined the entire Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) database and identified 263 samples in total, 
including 92 PDAC cell-line samples, 113 PDAC tissue samples and 58 adjacent 
normal pancreas tissue samples (Table 7). All these samples are generated from 
Affymetrix Human Genome U133 Plus 2.0 Array, which contains 54,675 probes 
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pointing to over 20,000 genes. Even though there are other expression samples from 
other numerous platforms, samples only from U133 Plus 2.0 Array are kept for further 
analysis. This is because it is the most common platform of PDAC samples in GEO; it 
covers the entire genome; data generated from this platform can be effectively 
integrated. Notably, all 92 cancer cell-line samples mined from GEO are also part of  
‘Cancer Cell Line Encyclopedia’ (CCLE) database [138], which offers a wealth of 
transcriptome profiles for more than 500 cell-lines across 30 different cancer types. 
In additional, for benchmark with other approaches, which requires gene 
mutation information, 183 PDAC tissue samples from ‘The Cancer Genome Atlas’ 
(TCGA) database, which provides both expression profiles and mutation information 
of tissue samples, are included in the study.  
Protein-Protein Interaction network STRING [19] is a comprehensive 
pathway database (https://string-db.org/), which accumulates numerous biological 
pathways and protein-protein interactions (PPI) derived from experiments and 
computational inference. PPI network version 11 data is included in the study from 
STRING. 
Gene essentiality from CRISPR-Cas9 screening data ‘Project Achilles’ [80-
82] (https://portals.broadinstitute.org/achilles) database offers a broad range of gene 
essentiality data derived from various perturbation experiments, including RNAi and 
CRISRP-Cas9. We choose CRISPR-Cas9 over RNAi for its less off-target effects [83], 
which is critical for accurately selecting drug targets for cancer. In total 22 PDAC cell-
lines that consists of 74,222 sgRNAs are included in this study.  
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Existing drug targets DrugBank [139] database contains all FDA approved 
drugs and corresponding targets. All these drugs are downloaded and then mapped 
them onto 1,769 targets, of which 313 genes are targets of cancer drugs. 
Existing synthetic lethal pairs Synthetic lethality (SL) reflects a type of 
genetic interaction between two genes such that simultaneous perturbations of the two 
genes result in significantly more cell death than cell death caused by perturbating 
either one of genes [140]. SynlethDB database consists of SL pairs curated from 
biochemical experiment, other related databases, computational predictions and text 
mining [140]. Documented SL pairs and their SL scores from SynlethDB are utilized 
for benchmarks and validations. 
Drug sensitivity data NCI60 database [141] offers numerous drug sensitivity 
measures over a broad range of cancer cell-lines. drug sensitivity information from 
NCI60 are included to validate predictions from DSCNi. 
6.2.2 Methods 
Defining the influence of targets towards the network Given an undirected 
network 𝐺𝐺 =< 𝐶𝐶,𝐸𝐸 >, where 𝐶𝐶 is the node set and 𝐸𝐸 is the edge set. A target node 
𝑇𝑇 can cause towards after 𝐺𝐺  being knocked-out can be defined as the sum of its 
influence towards every other node: 
𝑇𝑇𝐼𝐼(𝑇𝑇 ) = ∑ 𝑠𝑠[𝑁𝑁𝑖𝑖|𝑃𝑃𝑎𝑎(𝑁𝑁𝑖𝑖)]𝑖𝑖𝑖𝑖𝑉𝑉  (28) 
Where 𝑇𝑇𝐼𝐼 indicates target information, 𝑁𝑁  indicates a node, 𝑃𝑃𝑎𝑎(𝑁𝑁𝑖𝑖) indicates the 
parent set of 𝑁𝑁. The term 𝑠𝑠[𝑁𝑁 |𝑃𝑃𝑎𝑎(𝑁𝑁 )] thus indicates the influence towards 𝑁𝑁 . 
Hence, the objective is to maximize formula (28). 
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Different routing methods will cause different 𝑃𝑃𝑎𝑎(𝑁𝑁 ) , which further causes 
different 𝑠𝑠 . In this study three different routing methods, which are displayed in 
Figure14, are examined and benchmarked.  
Assume that edge weight indicates the correlations between nodes. Consider 
𝑇𝑇1 the target to be knocked out, the influence it can cause with three different routing 
methods can be defined as: 
Heaviest (Most correlated) Paths: in an undirected network, the distance 
between two nodes are defined as the distance of shortest/most correlated path. In 
Figure.14(b), each node 𝑁𝑁  has one heaviest path to 𝑇𝑇1. In this case, the parent set 
𝑃𝑃𝑎𝑎(𝑁𝑁 ) = 𝐶𝐶 , where 𝐶𝐶  indicates the set of nodes in the heaviest path. 
Random Walk (Figure 14(c)): starting from 𝑇𝑇1 , each node 𝑁𝑁   is randomly 
visited. This process takes certain number of  𝑃𝑃𝑎𝑎(𝑁𝑁 ) = 𝑁𝑁𝑖𝑖 where 𝑁𝑁𝑖𝑖 is the first node 
that visited 𝑁𝑁 . 
Diffusion: starting from 𝑇𝑇1 , each node is visited in a hierarchical order. 
𝑃𝑃𝑎𝑎(𝑁𝑁 ) = 𝐶𝐶, where 𝐶𝐶 indicates the parent nodes from the higher tier and connected 
sibling nodes from the same tier. For instance, in Figure14(d), when 𝑇𝑇1 is knocked out, 
a tree-like hierarchical structure is constructed using T1 as root to point out the tiers 
being sequentially influenced. Clearly there are 5 tiers in the hierarchical structure and 
the influence is transmitted from tier 1 to tier 5. The rationale behind it contains two 
folds: 1. Since we are handling an undirected network, a parent set is defined as a set 
of its directed parents and connected sibling nodes. Biological network is a complex 
and redundant system. 2. Influence can echo between connected sibling nodes. 
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Eventually diffusion method is selected and applied in the DSCN and DSCNi 
algorithm. The evidence of choosing diffusion method among three routing method in 
is described in section 6.3.1. 
As indicated in Figure 15, the algorithm generally consists of five steps: 
Step 1: Construct functional networks. In this step two integrated functional 
networks, namely tissue network 𝐺𝐺𝑛𝑛  and cell-line network 𝐺𝐺𝑐𝑐 are constructed.  
𝐺𝐺𝑛𝑛 consists of a skeleton from STRING PPI network, edge weights from pair-
wise Pearson correlations between genes in tumor samples, and node weights from 
tumor versus normal fold change. Assume there are in total n genes (nodes) in 𝐺𝐺𝑛𝑛, a 
affinity matrix 𝑅𝑅𝑛𝑛 is constructed to denote the edge weights: 





Where 𝑤𝑤ab, 𝑎𝑎, 𝑏𝑏 ∈ (1,𝑚𝑚) in the matrix indicate the edge weight (correlation) between 
gene a and b in the tissue network. 






Where 𝑤𝑤𝑖𝑖 in the matrix is the tumor versus normal fold change of gene 𝑖𝑖.  
𝐺𝐺𝑐𝑐 consists of an identical skeleton from the same STRING PPI network, edge weight 
from pair-wise gene correlations in cell-line samples, and node weight from CRISPR-
Cas9 screening data. Similarly, we defined affinity matrix 𝑅𝑅𝑐𝑐 and diagonal matrix 𝐷𝐷𝑐𝑐 
to indicate the edge weights and node weights in cell-line network 𝐺𝐺𝑐𝑐. 
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Step 2: Construct corresponding Laplacian matrices. Laplacian matrices are 
then constructed for representing the network structure of 𝐺𝐺𝑛𝑛 and 𝐺𝐺𝑐𝑐. The Laplacian 
matrix is defined as: 
𝐿𝐿 = 𝐷𝐷 − 𝑅𝑅 (31) 
Where D and S indicate diagonal matrix and affinity matrix, respectively. 𝐿𝐿𝑛𝑛 and 𝐿𝐿𝑐𝑐 
are constructed for tissue network and cell-line network, respectively.  
Step 3: Perform spectral clustering to tissue Laplacian matrix. To obtain 
disease related subnetworks, a spectral clustering is performed on 𝐺𝐺𝑛𝑛, which can be 
generally described as: for the Laplacian matrix 𝐿𝐿𝑛𝑛 , a eigen-decomposition is 
performed while eigenvectors that corresponds to 𝑘𝑘 smallest non-null eigenvalues 
are subsequently extracted. K-means algorithm is then performed for these k 
eigenvectors to get clusters (subnetworks). The steps of performing spectral clustering 
can be described as: 















In this step, 𝐿𝐿𝑛𝑛 is normalized to 𝐿𝐿′𝑛𝑛 so that 𝐿𝐿′𝑛𝑛 becomes positive semi-definite. Here 
𝑎𝑎𝑏𝑏𝑠𝑠() indicates the absolute operation. In Laplacian matrix 𝐿𝐿′𝑛𝑛, all diagonal elements 
are positive while all other elements are negative. And row sum of non-diagonal 
elements is equal to its corresponding diagonal.  
Perform eigen decomposition for matrix 𝐿𝐿′  and obtain the spectrum 
𝐸𝐸={𝜆𝜆1,𝜆𝜆2 … 𝜆𝜆𝑛𝑛}, where 𝜆𝜆𝑖𝑖 indicate the 𝑖𝑖th smallest eigen values. Decomposition for a 
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positive semi-definite matrix results in a set of non-negative eigen values: 0 = 𝜆𝜆1 ≤
𝜆𝜆2 ≤ ⋯ ≤ 𝜆𝜆𝑛𝑛.  
Pick 𝑘𝑘  smallest non-negative eigenvalues { 𝜆𝜆𝑖𝑖, … , 𝜆𝜆𝑖𝑖+𝑘𝑘 } and their corresponding 
eigenvectors, each of which is a n ∗ 1 vector. Combining 𝑘𝑘 eigenvectors results in a 
𝑚𝑚 ∗ 𝑘𝑘 matrix. 
Now the combination results in 𝑚𝑚 ∗ 𝑘𝑘  matrix, where 𝑚𝑚  corresponds to 𝑚𝑚 
nodes and each of them has 𝑘𝑘 values (coordinates) in this matrix. These values can 
be used to calculate pair-wise Euclidean distances. K-means clustering is then 
performed for 𝑚𝑚 nodes. The initial number of K’ in K-means is not associated with 
number of selected eigenvectors 𝑘𝑘. To select the K’ that result in a good fitness, an 
intuitive approach is applied: from K’=2 to the number of total number of variables, K-
means algorithm is continuously executed while Hartigan’s number is calculated at the 
same time. Hartigan’s number is a measure of the clustering quality by comparing two 
clustering results. The first K’ that result in Hartigan’s number less than 10 is then 
selected. Obviously, this scheme of picking K’ doesn’t guarantee global optima.  
K-means clustering leads to K’ exclusive clusters (subnetworks), each of which 
contains several node names. From the whole network 𝐺𝐺𝑛𝑛 , subnetworks are then 
extracted according for each cluster. The corresponding subnetworks of these clusters 
are named 𝑔𝑔𝑛𝑛1, …𝑔𝑔𝑛𝑛𝑘𝑘 respectively.  
Step 4: Map tissue subnetworks onto cell-line subnetworks and measure the 
similarities. Since 𝐺𝐺𝑛𝑛 and 𝐺𝐺𝑐𝑐  shares identical network structure, for each 𝑔𝑔𝑛𝑛1, …𝑔𝑔𝑛𝑛𝑘𝑘, 
corresponding subnetworks 𝑔𝑔𝑐𝑐1, …𝑔𝑔𝑐𝑐𝑘𝑘  are extracted from cell-line network using their 
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common node names. Till this point, clustering results from Tissue subnetworks have 
been mapped onto cell-line subnetworks. For each subnetwork pair <𝑔𝑔𝑛𝑛i,𝑔𝑔𝑐𝑐i >, 𝑖𝑖 ∈
(1,𝑘𝑘) , the similarity between tissue and cell-line are measured using the following 
scheme. 
For each <𝑔𝑔𝑛𝑛i,𝑔𝑔𝑐𝑐i>, 𝑖𝑖 ∈ (1,𝑘𝑘), to make them comparable, cell-line diagonal 

















Where 𝑤𝑤𝑐𝑐,𝑘𝑘  and 𝑤𝑤𝑛𝑛,𝑘𝑘  denote weight of node 𝑘𝑘 ∈ (1,𝑚𝑚)  in cell-line network and 
tissue network respectively. 𝑚𝑚 is the total number of nodes in 𝑔𝑔𝑛𝑛i and 𝑔𝑔𝑐𝑐i. Till this 
stage, the node weight is normalized. 
For each <𝑔𝑔𝑛𝑛i,𝑔𝑔𝑐𝑐i>, 𝑖𝑖 ∈ (1,𝑘𝑘), two Laplacian matrices are constructed using 
formula (34) and (35). 
𝐿𝐿𝑛𝑛i
 = 𝐷𝐷𝑛𝑛i − 𝑅𝑅𝑛𝑛i (34) 
𝐿𝐿𝑐𝑐i
 = 𝐷𝐷′𝑐𝑐i − 𝑅𝑅𝑐𝑐i (35) 
Obviously, after node weight normalization, Trace (𝐿𝐿𝑐𝑐i )=Trace (𝐿𝐿𝑛𝑛i ). Same traces 
indicate same spectrum (eigenvalues), which further indicate two matrices are in the 
same scale. Now edge weights (non-diagonal elements) are adjusted accordingly 

















Where 𝑤𝑤𝑖𝑖 indicate node weight of node 𝑖𝑖 , 𝑤𝑤𝑖𝑖𝑘𝑘 indicates edge weight between node 
𝑖𝑖 𝑎𝑎𝑚𝑚𝑑𝑑 𝑘𝑘 ,  𝑖𝑖,𝑘𝑘 ∈ (1,𝑚𝑚) . M is the total number of node within each subnetwork. We 
normalize matrix for both 𝑔𝑔𝑛𝑛i 𝑎𝑎𝑚𝑚𝑑𝑑 𝑔𝑔𝑐𝑐i to get normalized Laplacian 𝐿𝐿′′𝑛𝑛i
 and 𝐿𝐿′′𝑐𝑐i. Till 
this step, all edges (non-diagonal elements) in both Laplacian matrices acquired node 
features during normalization. Notably, node weight and edge weight can be either 
positive or negative in 𝐿𝐿′′. The original directions (positive or negative) of node weights 
and edge weights are kept in the process to accurately measure their distances. 
For two corresponding subnetworks 𝑔𝑔𝑛𝑛i 𝑎𝑎𝑚𝑚𝑑𝑑 𝑔𝑔𝑐𝑐i, their distances between their 
Laplacian 𝐿𝐿′′𝑛𝑛i




 (𝑖𝑖, 𝑗𝑗) −𝑚𝑚𝑗𝑗=1𝑚𝑚𝑖𝑖=1 𝐿𝐿′′𝑐𝑐i(𝑖𝑖, 𝑗𝑗)) 
2, 𝑖𝑖 ≠ 𝑗𝑗 (37) 
The term L′′ (𝑖𝑖, 𝑗𝑗) 𝑖𝑖 ≠ 𝑗𝑗 indicate the edge weight between node i and j in a given 
Laplacian matrix. The term (𝐿𝐿′′𝑛𝑛i
 (𝑖𝑖, 𝑗𝑗) − 𝐿𝐿′′𝑐𝑐i
 (𝑖𝑖, 𝑗𝑗)) 2 indicate the Euclidean distance 
between the same edge in two Laplacian matrices.  
Step 5: Score and rank target combinations with cell-line subnetworks. This 
step can be further divided into three processes: score first target, adjust network, 
score second target given first target. Here this score is defined as Target influence 
(TI).  
For each target 𝑇𝑇𝑎𝑎 of FDA approved drugs, the diffusion routing method is 
applied for measuring its influence towards other nodes. In Tier 1, 𝑇𝑇1 is the target 
being knocked out, it does not depend on any other node but itself. Hence, the 
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influence 𝑅𝑅(𝑇𝑇1)= 𝑊𝑊𝑇𝑇1, where 𝑊𝑊𝑇𝑇1 is the node weight of 𝑇𝑇1. In the following tiers, for 
each node, the influence it can cause consists of two parts: the influence from itself 
and the transmitted influence from its parent set. For instance, in Fig. 14(d), the 
influence of node 𝑁𝑁5 can be described as: 𝑅𝑅(𝑁𝑁5) =  𝑊𝑊(𝑁𝑁6,𝑁𝑁5)𝑊𝑊𝑁𝑁5 +𝑊𝑊(𝑁𝑁3,𝑁𝑁5)𝑊𝑊𝑁𝑁5 . In 
summary, the total influence that a network can get after a target 𝑇𝑇a being knocked 
out is the sum of the influence of all nodes can get within the network, which can be 
further described as: 
𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎) = 𝑅𝑅(𝑇𝑇a) + ∑ 𝑅𝑅(𝑁𝑁k)𝑘𝑘∈𝑔𝑔𝑐𝑐(𝑇𝑇𝑎𝑎)  (38) 
Where 𝑇𝑇a  is the target and 𝑁𝑁k  represents any other member genes in this 
subnetwork 𝑔𝑔𝑐𝑐(𝑇𝑇𝑎𝑎). In other words, 





Where m is the total number of member genes within the subnetworks 𝑔𝑔𝑐𝑐(𝑇𝑇𝑎𝑎). 𝑃𝑃𝑁𝑁𝑘𝑘
𝑔𝑔𝑐𝑐(𝑇𝑇𝑎𝑎) 
is the parent set of 𝑁𝑁𝑘𝑘 with the subnetwork 𝑔𝑔𝑐𝑐(𝑇𝑇𝑎𝑎). 𝑁𝑁𝑗𝑗 is any member node within the 
parent set. 𝑊𝑊𝑁𝑁𝑘𝑘 indicates the node weight of 𝑁𝑁𝑘𝑘. 𝑊𝑊(𝑁𝑁𝑘𝑘,𝑁𝑁𝑗𝑗) indicates the edge weight 
between 𝑁𝑁𝑘𝑘 and 𝑁𝑁𝑗𝑗. 
After one target being knocked out, the corresponding subnetwork will change 
in terms of node weight and edge weight. Due to the lack of expression data of 
before/after CRISPR-Cas9 screening, these changes need to be inferred. For a target 
being hypothetically knocked-out, its expression level varies across samples. We 
divided samples into two groups based on its mean expression values and the low 
expression group is used to represent its expression state after being knocked-out. 
Hence, the new pairwise correlation of other genes are generated from the low 
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expression group and updated to the network as edge weights. Similarly, the 
essentiality score is recalculated using the less essentiality subgroup of the given 
target. Till this point, the node weight and edge weight are updated in the 
corresponding subnetwork. In DSCNi, since expression profile (both tissue and cell-
line) of one sample is taken as input, only edge weight will be changed in the 
corresponding subnetwork. 
Given a target 𝑇𝑇a being knocked out and an adjusted subnetwork, for each of 
the rest target 𝑇𝑇b of FDA approved drugs, the combined influence of <𝑇𝑇𝑎𝑎 ,𝑇𝑇𝑎𝑎 > is 
measured with the following formula: 
𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎 ,𝑇𝑇𝑎𝑎) = 𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎) + 𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎|𝑇𝑇𝑎𝑎) (40) 
Where 𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎) is defined in formula 11 and 𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎|𝑇𝑇𝑎𝑎) is defined as: 
𝑇𝑇𝐼𝐼(𝑇𝑇𝑎𝑎|𝑇𝑇𝑎𝑎) = 𝑊𝑊𝑇𝑇𝑏𝑏





Where 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏|𝑇𝑇𝑎𝑎) indicates the subnetwork 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏) after 𝑇𝑇𝑎𝑎 being knocked out. The 
weight of the network may or may not be adjusted by this operation. If two targets are 
not in the same subnetwork, then 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏|𝑇𝑇𝑎𝑎) = 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏), which indicates subnetwork 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏) 
are not adjusted based on the knock-out of 𝑇𝑇𝑎𝑎 . If two targets are in the same 
subnetwork, then 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏|𝑇𝑇𝑎𝑎) ≠ 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏). 
The first term indicates the influence of second target 𝑇𝑇𝑎𝑎  towards its 
subnetwork 𝑔𝑔𝑐𝑐(𝑇𝑇𝑏𝑏), given the fact that its weight might or might not be adjusted after 
𝑇𝑇𝑎𝑎 being knocked out. The second term indicates influence from nodes not in tier 1.  
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6.3 Results 
6.3.1 Routing method selection 
In section 6.2.1, three different routing methods are proposed for evaluating 
the influence of a given target towards the network. These methods are benchmarked 
by calculating the score difference between synthetic lethal pairs and non-synthetic 
lethal pairs. 23 Pancreatic specific SL pairs exist in SynlethDB. These SL pairs 
correspond to 15 genes. Two groups are then constructed: a group of 46 SL pairs (23 
pairs with order) and a group of 164 non-SL pairs, which are all possible combinations 
of 15 genes minus 46 SL pairs. Even though SL pairs are not drug targets, and DSCN 
only calculated combination scores for existing drug targets. We assumed them to be 
drug targets and calculated their combination scores for three different methods. 
Independent T-test was performed between SL and non-SL pair groups. Two scales of 
network are also treated as variables in the benchmark: ‘global’ network indicates 
whole genome network before spectral clustering process mentioned in section 6.2.2 
step 3; ‘local’ network indicates subnetworks after spectral clustering process. Targets 
influence different number of nodes within two different networks.  
From Figure 16, it can be observed that SL pair group has a significantly lower 
score than non-SL pair group while using diffusion method under local network. This 
segregation fails to occur with other routing methods under both local and global 
network. This proves the necessity of performing spectral clustering and choosing 
diffusion method in DSCN. 
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6.3.2 Benchmark between DSCN, VIPER and Opticon 
To measure the accuracy of DSCN, we compared its predictions with 
predictions from two other algorithms: Opticon and VIPER, both of which use 
expression profiles to predict synergistic master regulators that control the entire 
subnetworks. VIPER takes expression profile from both tumor and normal samples to 
predict the corresponding regulon, which is a set of regulators and their targets. On 
top of that, it infers synergies among regulators. Opticon requires both expression 
profile from tumor samples and corresponding mutation information as input to infer 
first infer master regulators then predict synergies among them. PDAC expression data 
described in Table 7 is used and all 6,550 PDAC mutations obtained from TCGA as 
common input to benchmark the predictions for three algorithms. 
In total, DSCN, VIPER and Opticon predicted 37,275, 2778 and 191 
combinations. All of them are mapped onto SynlethDB, which consists of 12,821 SL 
pairs. Surprisingly, neither VIPER nor Option has any overlap with documented SL 
pairs while DSCN has 936 overlapped synergistic combinations. We then compared 
the rank of 936 overlapped SL pairs and 79 overlapped PDAC specific SL pairs using 
spearman correlation test (Table 8). Under both PDAC specific and all documented SL 
pairs settings, predicted ranks from DSCN maintains a relatively high correlations with 
documented SL pairs in SynlethDB. Moreover, predicted scores of 79 PDAC specific 
SL pairs are significantly lower than scores of 6,162 random combinations under 
independent T-test (T=-1.85, p=0.05). This shows consistency of T-test result from 
section 6.3.1. 
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All benchmark work has been done on supercomputer ‘Carbonate’ from 
Indiana University. DSCN spent 12 hours on a single CPU core to complete the search. 
shortest runtime among three algorithms. Although DSCN provided the option of 
executing algorithms in parallel, in the benchmark it is executed with single thread. 
Most of the computational time of VIPER is on generating a whole genome mutual 
information network using ARACNe [142], which requires ~141 hours to reconstruct 
such large scale network. Opticon mainly consists of two computational tasks: 
calculating subnetworks and calculating null distributions, each of which costs ~160 
computation hours. Even though Opticon optimize the calculation by simultaneously 
submitting hundreds of jobs on supercomputer. The overall speed remains the slowest. 
6.3.3 Top ranked drug combinations and associated subnetworks 
For all overlapped 1,437 drug targets, all possible combinations among them 
are calculated using PDAC data. Notably, genes involved in top 230 combinations are 
from the same subnetwork (No.42). Table 9 displays the top 10 ranked target 
combinations. All of them have relatively close TI scores. Survival analysis were 
performed for calculating hazard ratio of high expression group versus low expression 
group using clinical information from TCGA. Interestingly, most of top ranked 
combinations are TFRC plus another genes and most TFRC involved combinations 
show significant high hazard ratios. Transferrin receptor (TFRC) encodes a surface 
receptor for cellular iron intake, It is reported to be highly expressed in PDAC and high 
associated with PDAC cancer growth and survival [143]. Recent studies suggest 
several key pathways of inducing Ferroptosis, such as MAPK and Ros [144]. Hence, 
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targeting upstream genes (e.g. MAP2K2, EGLN2) along with downstream genes (e.g. 
TFRC, FTL) might lead to a synergistic effect of inducing Ferroptosis. This explains 
why combinations listed in Table 9 are in the same subnetwork and have TI scores.  
Figure 17 and Figure 18 display the tissue specific network and cell-line specific 
network of subnetwork No.42. In both figures, red and blue shades on edges indicate 
positive and negative correlations. Red/blue shades on nodes indicate over-
expression/under-expression in tissue network and positive/negative gene essentiality 
in cell-line network. Dimond and round shapes of node indicate target genes and non-
target genes, respectively. Shades of colors indicate intensity. Due to the high density 
of the subnetwork, only edges associated with target nodes are drawn. Edges among 
target nodes are highlighted with colors. The distance between these two networks are 
16.65 (min=0, max=239) and ranked 100 among all 260 subnetworks. Given the fact 
that this subnetwork is the fourth largest subnetworks among all subnetworks, two 
networks share significant similarities. These similarities also reflect on the nodes and 
edges. All target nodes, most of the non-target nodes and edges share the same colors 
(directions). Together with the identical network topology, cell-line and tissue data 
shows high consistency on this subnetwork. 
6.3.4 Comparison between predictions of DSCNi and existing drug synergies in 
cell-lines 
Due to the limited number of PDAC cell-lines (N=1) and related combinational 
drug treatments (N=5), predictions of DSCNi using Triple negative breast cancer 
(TNBC) cell-lines are used and tested. All TNBC cell-lines from various databases are 
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examined to check the overlap, including transcriptomic data from CCLE database, 
drug sensitivity data from NCI60 database and CRISPR gene essentiality data from 
‘Project Achilles’. ‘HS578T’ is selected as the candidate cell-line and its omics data is 
extracted as well, including its gene essentiality value and drug sensitivity. 
Transcriptomic data of 12 TNBC cell-lines from CCLE and 115 tissues from TCGA are 
selected accordingly. Target combinations for sample ‘TCGA-A1-A0SK’ via cell-line 
HS578T are predicted and then validated using drug sensitivity from NCI60 database. 
In total, scores for all 2,063,532 combinations of 1,437 existing drug target are 
predicted. Among them, 14,067 overlaps with 1,031 drug combinations. Bliss score 
[145] measures expected effect of two compounds being independently acting. Two 
compounds are considered to be synergistic if their bliss score>0.12 [146]. Firstly bliss 
scores between 1,031 overlapped drug combinations and all 5,227 drug combinations 
for ‘HS578T’ are compared. Bliss scores of overlapped groups are significantly higher 
than all drug combinations (T=2.35, P=0.02). 
A high Drug synergy (bliss score) does not necessarily reflect a high lethality. 
It reflects the additive effects when two drugs are simultaneously acting. To validate 
the predictions from DSCNi using drug synergy data, the synergistic effect between 
target combinations and drug synergy need to be compared. Here we defined a 
predicted target combination to be synergistic if their TI score is higher than the sum 
of TI score of each target. A contingency table (Table 10) is created for measuring the 
association between predicted target combinations and corresponding drug 
combinations. In the table, PS, PN, DS and DN indicate predicted synergistic target 
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combination, predicted non-synergistic target combination, target combinations 
reflected in drug synergies, target combinations not reflected in drug synergies 




, 𝜙𝜙 𝜖𝜖 [−1,1] (42) 
where 𝜒𝜒2  indicates the chi-square statistic. 𝜙𝜙 = ±1  reflects maximum 
positive/negative correlations between rows and columns in contingency table.  
Predicted synergistic target combinations (PS) has a high positive correlation (0.32) 
with target combinations reflected in drug synergies. Notably, no PS & DN 
combinations occurs in Table 10, indicating that predictions from DSCNi has very few 
false positive rates. 
7,069 out of 14,067 discovered target combinations are identified as synergistic 
combinations. Top 72 of them ranked by TI score are associated with MAPK3 and 
another genes, which further point to ARSENIC TRIOXIDE and another compounds. 
This is due to the strong synergistic effect between MAPK3 and many other genes. 
MAPK3 is often highly expressed in TNBC due to the activation of Ras/MAPK pathway 
(Hazard ratio =1.5, p<0.01). Signals from Ras pathway are transmitted through Raf, 
MEK, MAPK1/3 to the nucleus to initiate downstream transcription factors such as 
MYC, ETS-1, ETS-2, and ELK-1, which further regulate cell proliferation and survival 
[147]. Inhibition of Ras/MAPK pathway has been proven as highly effective in treating 
advanced melanoma [148] and preventing/treating TNBC metastasis in vivo [149, 150]. 
ARSENIC TRIOXIDE (As2O3), which has been successfully applied in treating 
hematologic malignancies due to its capability of inducing cell apoptosis, has not been 
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widely applied on treating solid tumors, including TNBC. Recent studies suggest that 
inhibiting pathways such TNF, JAK and PI3K-Akt work in concert with As2O3 for better 
treating TNBC [151-154]. These findings coincide with the predictions of DSCNi. 
Other combinations in Table 11 are selected for their high bliss scores, TI 
scores and documented synthetic lethality. Among them LAPATINIB, DOCETAXEL, 
PACLITAXEL are the most common chemo drugs for treating TNBC and (PACLITAXEL, 
LAPATINIB) combinations are widely prescribed.  
6.4 Discussion 
DSCN is introduced as a method that uses tissue and cell-line models to 
discovery and rank target combinations according to their estimated lethality. With 
existing evidence from literature and database, it is demonstrated that:  
1. Using known SL pairs and non-SL pairs (random combinations of genes in 
these SL pairs) as inputs, DSCN clearly distinguishes two groups by their TI scores. 
This is mainly due to the selected routing method has the best capability of 
distinguishing two groups over other routing methods. 
2. Predictions from DSCN directly overlaps with documented SL pairs while 
other methods (VIPER and Option) failed to provide any direct overlaps between their 
predictions and documented SL pairs. VIPER and Opticon first predicts master 
regulators and then estimate the synergies among them, which limit their searching 
space. Two master regulators are not necessarily synergistic even though the 
subnetworks they control contain a lot of SL pairs. In contrast, even though DSCN is 
designed to predict combinations among targets that are associated with FDA 
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approved drugs, it is capable of predict any gene pairs that have expression value and 
essentiality, which broaden the searching space. Any potential SL pairs within the 
entire genome can be potentially discovered. Moreover, predictions from DSCN 
directly reflect the SL between two genes, which are more direct to understand and 
easier to be validated.  
3. Predicted ranks from DSCN align with documented SL pairs in terms of SL 
intensity, especially for top ranked predictions (top 20, Spearman corr=0.43). This 
shows great accuracy of predictions. Predicted ranks also align well with (Spearman 
corr=0.34) documented PDAC specific SL pairs, indicating a reasonably good 
specificity of the DSCN predictions under context specific scenario. 
Additionally, compared to VIPER and Opticon, DSCN requires the least 
computational time. VIPER requires ARACNe to pre-compute mutual information 
network, which cost roughly 6 days to generate with a whole genome scale. ARACNe 
does not have option to run in parallel. Opticon distributes whole task into hundreds of 
jobs, each of which requires various hours (from 3 hours to 50 hours) to complete. This 
process needs to be performed twice: one for disease-specific networks and one for 
null networks. Computational work of DSCN mainly consists of two parts: spectral 
clustering and scoring targets in subnetworks. The first part requires 2-5 hours and 
second part requires 12-24 hours for examining all possible combinations of all 1,423 
targets within the whole genome. The whole process can be even accelerated using 
multiple threads as DSCN allows user to flexibly choose the number of threads in 
parallel.  
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DSCNi undergoes the similar processes as DSCN to discover and rank target 
combinations for individuals. One TNBC sample from TCGA and one TNBC cell-line 
sample from CCLE are selected as input to predict target combinations. The 
predictions are validated using the following schemes: 
1. The predictions are compared with existing drug combination synergies. 
Predicted synergistic target combinations has a high positive correlation (0.32) with 
target combinations reflected in synergistic drug combinations (bliss>0.12). Moreover, 
predictions from DSCNi doesn’t have false positives, which is critical for the predictions 
to be applied in clinic.  
2. Drug combinations associated with top ranked synergistic target 
combinations are either widely used in clinic as treatment plans or frequently reported 
as novel treatment plans in literatures. Combinations containing As2O3 are top ranked 
because their associated target combinations are in the upstream and downstream 
areas of Ras/MAPK pathway, which have been already targeted for successfully 
treating hematologic malignancies and melanomas. The findings might benefit the 
As2O3 associated combinational therapies to be re-purposed on treating TNBC.  
3. For the top ranked target combinations, similarities between tissue 
subnetworks with and cell-line subnetworks are measured. Two networks are 
reasonably similar in terms of expression patterns and gene-gene correlations. This 






Figure 14 Three different routing methods (a) Original network. The numbers indicate 
edge weights (b) Heaviest paths between target node 𝑇𝑇1 are all the other nodes (c) 















Figure 17 Subnetwork No.42 in tissue specific network 
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Table 7 Compositions and sources of pancreatic omics-data 
GEO Expression data Perturbation 
data 


















































  GSE23952 
(3) 
  
92 samples 113 samples 58 samples 26 cell-lines 11,609,230 
connections 
1,769 
targets TCGA expression data 
 179 samples 4 samples 
 
Table 8 Spearman correlations between predicted target combinations and 
documented SL pairs 
Type Spearman 
Correlation 
P-value SL vs Non-
SL 
T-statistic P-value 
PDAC 0.34 <0.01 PDAC 0.34 <0.01 
Top 20 0.43 0.06 Top 20 0.41 0.06 
Top 40 0.25 0.11 Top 40 0.24 0.12 
Top 100 0.27 0.02 Top 100 0.24 0.01 
















Table 9 Top ranked target combinations and their statistics 






Pathways in concert with 
Ferroptosis 
EGLN1 TFRC -255.12 2.00 0.02 Hypoxia; Ferroptosis 
MAP2K2 TFRC -255.05 1.60 0.08 MAPK; Ferroptosis 
HPSE TFRC -255.01 1.50 0.06 Metabolism; Ferroptosis 
PPIC TFRC -254.86 1.80 0.05 Immune system; Ferroptosis 
FRK TFRC -254.86 1.80 0.05 Immune system; Ferroptosis 
EGLN1 COX7C -254.79 1.10 0.85 Hypoxia; Metabolism 
XDH TFRC -254.75 2.40 <0.01 Metabolism; Ferroptosis 
MAP2K2 COX7C -254.72 0.65 0.15 MAPK; Oxidative phosphorylation 
FTL TFRC -254.71 1.60 0.1 Ferroptosis; Ferroptosis 
HPSE COX7C -254.68 
1.10 0.7 Metabolism; Oxidative 
phosphorylation 
 
Table 10 Contingency table of predicted synergy and actual drug synergy 
Type PS PN Correlations 
DS 2594 7097 𝜙𝜙 = 0.32 




Table 11 Top ranked and selected target combinations and corresponding drug 
combinations from DSCNi 
Gene1 Gene2 Drug1 Drug2 Bliss TI_score Synleth_D
B score 






3.5 -6.96 0.5 
SMO MAP4 VISMODEGIB PACLITAXEL 14.9
3 
-12.93 0.5 












6.63 -69.80 NA 




10.1 -64.00 NA 
SMO MAPK3 VISMODEGIB ARSENIC 
TRIOXIDE 




7. Conclusion and Future Work 
7.1 Conclusion on FFBN algorithm (section 3) 
The benchmark studies show that GENIE3 has overall best AUROC and AUPR 
in silico network, and equally good AUROC but worse AUPR in yeast network 
compared to FFBN and FGS. Unlike GENIE3, FFBN infers the GRN purely in a data-
driven way. It doesn’t rely on existing prior knowledge to infer the network structure. 
Speed-wise, prior knowledge of TF and no-direction-inferring feature provides GENIE3 
the fastest speed among the three methods. FFBN maintains a significantly faster 
speed under different parameters and networks with different scales compared to FGS. 
The speed increase varies from 11% up to 96%, and the speed difference between 
FFBN and FGS becomes larger as the network becomes denser or larger. Taken 
together, FFBN shows ascendancy over FGS when reconstructing large and dense 
biological networks. This computation advantage is also reflected in the GRN 
constructions for CLM, PC, and PL cancer samples. FFBN was able to build up these 
GRNs in between 2,430 and 5,931 minutes, while FGS failed to generate a converged 
PL GRN, prohibiting any follow-up network comparison and pathway enrichment 
analyses. 
7.2 Conclusion on SCN algorithm (section 4) 
SCN is the first algorithm that can incorporate expression data, PPI data and 
gene perturbation data (CRISPR or RNAi) for selecting and ranking drug targets. The 
novelty of SCN algorithm mainly reflects on: i. SCN is the first algorithm that takes 
advantage of dimension reduction methods to integrate three different types of omics 
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data into a comprehensive network for drug target selection; ii. SCN utilized CRISPR 
data to benefit the target selection. The CRISPR data can mimic the real drug response 
of drugs; iii. SCN uses spectral clustering to reduce data dimensions to captures 
features on tissue-based omics-data and ranks drug targets on cell-line omics-data, 
which makes the target selection process more reliable. Spectral clustering was initially 
introduced to cancer biology for identifying novel subtypes of Triple Negative Breast 
Cancer (TNBC)  [155]. To our knowledge, it has never been used for selecting 
genotypic features from an integrated network. Despite the advantages, there is still 
room for SCN to improve. The possible future might include i. incorporate pathway 
information into target selection process for PDAC. Pathways information provide a 
different perspective of understanding the progression and treatment of PDAC [96, 156, 
157]. Targeting cancer related pathways can be a highly effective strategy for treating 
PDAC. Thus, it is necessary to incorporate pathway information into the drug target 
ranking and selection process; ii. Incorporate functional information into the target 
selection process. SCN algorithm ranked drug targets mainly based on differential 
expression, protein-protein interaction and tissue-target concordance. However, 
different proteins might have different docking capacities, which directly affects its 
potential to become a druggable target. Unfortunately, SCN algorithm does not take 
this information into account for ranking targets. Integrating this information into the 
whole process is necessary. 
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7.3 Conclusion on SCN website (section 5) 
SCN website offers a unique method of prioritizing actionable drug targets from 
multi-type omics data, including tissue and cell-line expression profiles, PPIs, CRISPR 
screening data and drug target information from DrugBank. Over 20,000 genes, 9606 
proteins, expression profile from >400 cell-lines across 24 different cancer types are 
included. For the first time in precision medicine, this platform integrates tissue data 
and cell-line data of cancers, enabling users to upload their own expression data to 
seek customized targets. Survival analysis is automatically performed using TCGA 
patient data so that users can validate their targets. Moreover, SCN website provides 
GSEA analysis for the prioritized targets to better mine the biological mechanisms 
associated with them. Additionally, evidence of clinical trials extracted from 
ClincalTrials.gov can provide more hints on how the identified targets can be applied 
in clinic.  
SCN website provides instructions of input, output files and general steps of 
SCN algorithm. It offers an complete set of example files, which contains example 
tissue expression data, cell-line expression data, all intermediate files generated 
during the algorithm processing and example output file so that users can easily 
understand and try the whole process.  
7.4 Conclusion on DSCN algorithm (section 6) 
DSCN and DSCNi has been validated as solid approaches for predicting 
lethality for combinational targets. Some of these combinational targets either serve 
as widely used in clinic. Other top ranked combinational targets are extensively studied 
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as promising treatment plans. Taken together, these predictions worth further 
investigation for either investigating the molecular mechanisms of cancer or 
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